

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances in endometrial cancer: a review... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/8-849/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/8-849" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances in endometrial cancer: a review of key clinical trials from 2015 to 2019" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances in endometrial cancer: a review of key clinical trials from 2015 to 2019.">
            <meta name="og:description" content="Read the latest article version by Lindsey M. Charo, Steven C. Plaxe, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="19036">
            <meta name="article-id" content="17408">
            <meta name="dc.title" content="Recent advances in endometrial cancer: a review of key clinical trials from 2015 to 2019">
            <meta name="dc.description" content="In the past few years, we have seen several important advances in understanding of and therapy for endometrial cancer. This review highlights key recent abstracts and publications in endometrial cancer from 2015 to 2019. We focus on clinical trials in surgical staging and the utility of sentinel lymph node mapping, adjuvant treatment for high-risk disease and HER2/neu-positive serous tumors, combination therapy for recurrent disease, molecular biology, and immunotherapy.">
            <meta name="dc.subject" content="uterine cancer, endometrial cancer">
            <meta name="dc.creator" content="Charo, Lindsey M.">
            <meta name="dc.creator" content="Plaxe, Steven C.">
            <meta name="dc.date" content="2019/06/12">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.17408.1">
            <meta name="dc.source" content="F1000Research 2019 8:849">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="uterine cancer">
            <meta name="prism.keyword" content="endometrial cancer">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2019/06/12">
            <meta name="prism.volume" content="8">
            <meta name="prism.number" content="849">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.17408.1">
            <meta name="prism.url" content="https://f1000research.com/articles/8-849">
            <meta name="citation_title" content="Recent advances in endometrial cancer: a review of key clinical trials from 2015 to 2019">
            <meta name="citation_abstract" content="In the past few years, we have seen several important advances in understanding of and therapy for endometrial cancer. This review highlights key recent abstracts and publications in endometrial cancer from 2015 to 2019. We focus on clinical trials in surgical staging and the utility of sentinel lymph node mapping, adjuvant treatment for high-risk disease and HER2/neu-positive serous tumors, combination therapy for recurrent disease, molecular biology, and immunotherapy.">
            <meta name="citation_description" content="In the past few years, we have seen several important advances in understanding of and therapy for endometrial cancer. This review highlights key recent abstracts and publications in endometrial cancer from 2015 to 2019. We focus on clinical trials in surgical staging and the utility of sentinel lymph node mapping, adjuvant treatment for high-risk disease and HER2/neu-positive serous tumors, combination therapy for recurrent disease, molecular biology, and immunotherapy.">
            <meta name="citation_keywords" content="uterine cancer, endometrial cancer">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Lindsey M. Charo">
            <meta name="citation_author_institution" content="Rebecca and John Moores UC San Diego Cancer Center, 3855 Health Sciences Drive #0987, La Jolla, CA, 92093-0987, USA">
            <meta name="citation_author" content="Steven C. Plaxe">
            <meta name="citation_author_institution" content="Rebecca and John Moores UC San Diego Cancer Center, 3855 Health Sciences Drive #0987, La Jolla, CA, 92093-0987, USA">
            <meta name="citation_publication_date" content="2019/06/12">
            <meta name="citation_volume" content="8">
            <meta name="citation_publication_number" content="849">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.17408.1">
            <meta name="citation_firstpage" content="849">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/8-849/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/8-849.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=19036 /> <input type=hidden id=articleId name=articleId value=17408 /> <input type=hidden id=xmlUrl value="/articles/8-849/v1/xml"/> <input type=hidden id=xmlFileName value="-8-849-v1.xml"> <input type=hidden id=article_uuid value=c33363e7-865d-4bbd-8969-eb53571975cc /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances in endometrial cancer: a review of key clinical trials from 2015 to 2019"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.17408.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.17408.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/8-849"
  },
  "headline": "Recent advances in endometrial cancer: a review of key clinical trials from 2015 to 2019",
  "datePublished": "2019-06-12T11:29:36",
  "dateModified": "2019-06-12T11:29:36",
  "author": [
    {
      "@type": "Person",
      "name": "Lindsey M. Charo"
    },    {
      "@type": "Person",
      "name": "Steven C. Plaxe"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "In the past few years, we have seen several important advances in understanding of and therapy for endometrial cancer. This review highlights key recent abstracts and publications in endometrial cancer from 2015 to 2019. We focus on clinical trials in surgical staging and the utility of sentinel lymph node mapping, adjuvant treatment for high-risk disease and HER2/neu-positive serous tumors, combination therapy for recurrent disease, molecular biology, and immunotherapy."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/8-849/v1",
            "name": "Recent advances in endometrial cancer: a review of key clinical trials..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances in endometrial cancer: a review of key clinical trials... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=19036 data-id=17408 data-downloads="" data-views="" data-scholar="10.12688/f1000research.17408.1" data-recommended="" data-doi="10.12688/f1000research.17408.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/8-849/v1/pdf?article_uuid=c33363e7-865d-4bbd-8969-eb53571975cc" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-17408-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-17408-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-17408-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Charo LM and Plaxe SC. Recent advances in endometrial cancer: a review of key clinical trials from 2015 to 2019 [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):849 (<a class=new-orange href="https://doi.org/10.12688/f1000research.17408.1" target=_blank>https://doi.org/10.12688/f1000research.17408.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-17408-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=17408 id=track-article-signin-17408 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/17408?target=/articles/8-849/v1">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=19036 /> <input name=articleId type=hidden value=17408 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances in endometrial cancer: a review of key clinical trials from 2015 to 2019</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Lindsey M. Charo<a href="https://orcid.org/0000-0002-4271-7195" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-4271-7195</div>,&nbsp;</span><span class=""><a href="mailto:splaxe@ucsd.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Steven C. Plaxe</span></a></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Lindsey M. Charo<a href="http://orcid.org/0000-0002-4271-7195" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-4271-7195</div>,&nbsp;</span><span class=""><a href="mailto:splaxe@ucsd.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Steven C. Plaxe</span></a></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 12 Jun 2019 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.17408.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Rebecca and John Moores UC San Diego Cancer Center, 3855 Health Sciences Drive #0987, La Jolla, CA, 92093-0987, USA<br/> <p> <div class=margin-bottom> Lindsey M. Charo <br/> <span>Roles: </span> Conceptualization, Investigation, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Steven C. Plaxe <br/> <span>Roles: </span> Conceptualization, Supervision, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=51794-49228></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=51793-49229></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> In the past few years, we have seen several important advances in understanding of and therapy for endometrial cancer. This review highlights key recent abstracts and publications in endometrial cancer from 2015 to 2019. We focus on clinical trials in surgical staging and the utility of sentinel lymph node mapping, adjuvant treatment for high-risk disease and HER2/neu-positive serous tumors, combination therapy for recurrent disease, molecular biology, and immunotherapy. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> uterine cancer, endometrial cancer </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Steven C. Plaxe (<a href="mailto:splaxe@ucsd.edu">splaxe@ucsd.edu</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Steven C. Plaxe </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2019 Charo LM and Plaxe SC. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Charo LM and Plaxe SC. Recent advances in endometrial cancer: a review of key clinical trials from 2015 to 2019 [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):849 (<a href="https://doi.org/10.12688/f1000research.17408.1" target=_blank>https://doi.org/10.12688/f1000research.17408.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 12 Jun 2019, <b>8</b>(F1000 Faculty Rev):849 (<a href="https://doi.org/10.12688/f1000research.17408.1" target=_blank>https://doi.org/10.12688/f1000research.17408.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 12 Jun 2019, <b>8</b>(F1000 Faculty Rev):849 (<a href="https://doi.org/10.12688/f1000research.17408.1" target=_blank>https://doi.org/10.12688/f1000research.17408.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d9063e148>Introduction</h2><p class="" id=d9063e151>In 2019, there will be an estimated 61,880 new cases of and 12,160 deaths from endometrial cancer<sup><a href="#ref-1">1</a></sup>. It is the most common gynecologic malignancy in the US and the only gynecologic cancer with increasing incidence and mortality<sup><a href="#ref-2">2</a></sup>. Tran and Gehrig published a comprehensive F1000 Faculty Review in January 2017<sup><a href="#ref-3">3</a></sup>. They outlined the genetic bases of endometrial cancer, novel surgical treatment, molecular targeted therapeutics, and current clinical trials. We invite you to reference their review for the groundwork of this article. Since their publication, we have seen several important advances in understanding and therapy, including surgical staging and the utility of sentinel lymph node (SLN) mapping, adjuvant treatment for high-risk disease and HER2/neu-positive serous tumors, combination therapy for recurrent disease, molecular biology, and immunotherapy. We focus on these recent advances.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d9063e169>Surgical staging: sentinel lymph node evaluation</h2><p class="" id=d9063e172>Lymph node involvement is a critical factor in determining prognosis and adjuvant therapy in endometrial cancer. As discussed in greater detail below, evidence supports a survival advantage for adjuvant chemotherapy in patients with stage III endometrial cancer; however, a similar benefit may not accrue to patients with locally advanced disease<sup><a href="#ref-4">4</a>–<a href="#ref-6">6</a></sup>. Complete staging lymphadenectomies have been associated with morbidity that impacts quality of life, including lymphedema, lymphocele formation, and neuralgia<sup><a href="#ref-5">5</a>,<a href="#ref-7">7</a>,<a href="#ref-8">8</a></sup>. Several criteria have been proposed to define patients in whom the risk is low enough to safely omit a staging lymphadenectomy. Most recently, the Korean Gynecologic Oncology Group showed that their criteria—endometrioid histology, no evidence of deep invasion or enlarged lymph nodes on magnetic resonance imaging (MRI), and pre-operative CA-125 of less than 35 units/mL—resulted in a negative predictive value of 97.1%<sup><a href="#ref-9">9</a></sup>; however, some criticize the cost and burden associated with obtaining pre-operative MRI and CA-125<sup><a href="#ref-10">10</a></sup>. SLN biopsies offer a compromise and have been shown to reduce risks of lymphedema and lymphocele<sup><a href="#ref-11">11</a></sup>.</p><p class="" id=d9063e204>In 2017, the results of the Fluorescence Imaging for Robotic Endometrial Sentinel lymph node biopsy (FIRES) trial were published<sup><a href="#ref-5">5</a></sup>. This large, multicenter, prospective cohort study enrolled patients with clinical stage I endometrial cancer and determined the sensitivity and negative predictive value of SLN mapping in detecting metastatic disease compared with the gold standard complete lymphadenectomy. FIRES investigators injected indocyanine green into the cervix and performed SLN mapping followed by pelvic lymphadenectomy with or without para-aortic lymphadenectomy. Pathologists assessed SLNs for metastases by hematoxylin and eosin (H&amp;E) staining. If the results were negative by H&amp;E, they performed cytokeratin immunohistochemistry (IHC) ultra-staging. They found an impressive 97% sensitivity and 99.6% negative predictive value<sup><a href="#ref-5">5</a></sup>.</p><p class="" id=d9063e215>In the FIRES trial, approximately 14% of patients did not map and approximately 34% of patients mapped to only one side, which would necessitate approximately 48% of patients to have a lymphadenectomy due to mapping failure. Conversely, over half of patients with endometrial cancer can be spared a complete staging lymphadenectomy with SLN mapping. Some have raised concerns regarding missing isolated para-aortic metastases in SLN mapping<sup><a href="#ref-12">12</a></sup>, especially in those with the highest prevalence of para-aortic metastases (high-grade and deeply invasive tumors)<sup><a href="#ref-13">13</a></sup>. One study showed that SLN biopsies detected more metastatic nodal disease compared with selective pelvic and para-aortic lymphadenectomies<sup><a href="#ref-14">14</a></sup>. This was recently confirmed in a meta-analysis of 3,536 patients in six studies, showing higher positive pelvic nodal detection rates, no difference in para-aortic nodal detection rates, and no difference in overall recurrence or nodal recurrence rates in SLN compared with complete lymphadenectomy<sup><a href="#ref-15">15</a></sup>. Additionally, the risk of para-aortic recurrence in patients with positive pelvic nodes and unassessed para-aortic nodes is only 4%<sup><a href="#ref-16">16</a></sup>. In regard to high-risk histology, a prospective study examined women with grade 3 (endometrioid, serous, clear cell, and carcinosarcoma) endometrial cancer by SLN biopsy followed by full pelvic and para-aortic lymphadenectomy; they found 95% sensitivity and 98% negative predictive value and bilateral mapping rates of 58% and unilateral mapping rates of 40%, supporting the use of SLN in high-risk patients<sup><a href="#ref-17">17</a></sup>. Additionally, 27% of patients in the FIRES trial and 27 to 100% of patients in the six studies included in the meta-analysis had high-grade histology<sup><a href="#ref-5">5</a>,<a href="#ref-15">15</a></sup>.</p><p class="" id=d9063e250>In order to adequately evaluate nodal status, patients who do not map to one or both sides should have unilateral or bilateral complete lymphadenectomies, respectively. Additionally, all enlarged or suspicious lymph nodes should be removed, regardless of SLN mapping<sup><a href="#ref-18">18</a></sup>. According to the Society of Gynecologic Oncology (SGO) Clinical Practice Statement, individual surgeons should consider performing full lymphadenectomy while their personal experience is accrued (20 to 30 cases) to ensure that they, and their pathologists, demonstrate acceptable sensitivity and negative predictive value. The decreased morbidity, high sensitivity, and high negative predictive value make SLN evaluation an appealing and standard option, which is supported by both the National Comprehensive Cancer Network (NCCN) and the SGO; however, some surgeons may choose to limit its use to intermediate-risk populations until further data accrue. Additionally, data to guide adjuvant treatment (that is, adding extended-field radiation) in patients with positive pelvic lymph nodes with unknown para-aortic nodal status are needed.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d9063e260>Adjuvant treatment for high-risk endometrial cancers</h2><p class="" id=d9063e263>Most endometrial cancers will be cured with surgery alone. However, many advanced-stage and some early-stage cancers will recur. Multiple studies have characterized the risk of post-surgical recurrence and tried to identify adjunctive therapies to reduce it. High-risk factors include tumor grade, tumor size, cell type, depth of myometrial invasion, presence of lymphovascular space invasion (LVSI), and stage<sup><a href="#ref-13">13</a>,<a href="#ref-19">19</a>–<a href="#ref-21">21</a></sup>. Because of randomized controlled trials and retrospective series comparing adjuvant chemotherapy with radiation therapy, there has been optimism that chemotherapy may reduce the risk of distant recurrence and improve survival for patients with high-risk disease. However, as outlined below, chemotherapy has shown improvement in overall survival (OS) in advanced-stage disease but not in high-risk, early-stage patients. Radiation therapy is known to be quite effective in achieving local control, but improvement in OS has not been realized<sup><a href="#ref-6">6</a>,<a href="#ref-19">19</a>,<a href="#ref-22">22</a>,<a href="#ref-23">23</a></sup>. Recently, the results of three important trials that evaluated combined radiation and chemotherapy aimed at reducing rates of both local and distant recurrence were presented: the results of GOG 249 were published in the <i>Journal of Clinical Oncology</i> in April 2019<sup><a href="#ref-24">24</a></sup>, Gynecologic Oncology Group (GOG) protocol 258 was presented in abstract form<sup><a href="#ref-25">25</a></sup>, and the results of Post-Operative Radiation Therapy in Endometrial Carcinoma 3 (PORTEC 3) were published in <i>Lancet Oncology</i> in March 2018<sup><a href="#ref-26">26</a></sup>. GOG 249 investigated the role of adjuvant chemotherapy and vaginal brachytherapy in early-stage, high-risk patients<sup><a href="#ref-24">24</a></sup>, whereas GOG 258<sup><a href="#ref-24">24</a>–<a href="#ref-26">26</a></sup> and PORTEC 3<sup><a href="#ref-24">24</a>–<a href="#ref-26">26</a></sup> examined the role of combined chemotherapy and radiation in higher-risk cohorts. <a href="#T1">Table 1</a> outlines the details of these and other key trials that guide adjuvant therapy in high-intermediate and high-risk endometrial cancer.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Key trials guiding adjuvant therapy in high-intermediate and high-risk endometrial cancer.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d9063e340 class=n-a></a><thead><a name=d9063e342 class=n-a></a><tr><a name=d9063e344 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d9063e346 class=n-a></a>Trial<br class=br>Years of accrual<br class=br>Number of patients<br class=br>assessed<br class=br>First author<br class=br>Publication year</th><th align=left colspan=2 rowspan=1 valign=top><a name=d9063e359 class=n-a></a>Eligibility</th><th align=left colspan=1 rowspan=1 valign=top><a name=d9063e362 class=n-a></a>LN<br class=br>assessed</th><th align=left colspan=1 rowspan=1 valign=top><a name=d9063e367 class=n-a></a>Arms</th><th align=left colspan=1 rowspan=1 valign=top><a name=d9063e370 class=n-a></a>Aims</th><th align=left colspan=2 rowspan=1 valign=top><a name=d9063e374 class=n-a></a>Outcomes</th><th align=left colspan=1 rowspan=1 valign=top><a name=d9063e377 class=n-a></a>Conclusions</th></tr></thead><tbody><a name=d9063e382 class=n-a></a><tr><a name=d9063e384 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e386 class=n-a></a>PORTEC<br class=br><br class=br>1990–1997<br class=br><br class=br>N = 714<br class=br><br class=br>Creutzberg <i>et al</i>.<br class=br>(2000)<sup><a href="#ref-22">22</a></sup></td><td align=left colspan=2 rowspan=1 valign=top><a name=d9063e407 class=n-a></a>Stage I:<br class=br><br class=br>IB<sup><a href="#fn1">a</a></sup> G2–3<sup><a href="#fn2">b</a></sup><br class=br>IC G1–2<br class=br>S/CC</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e424 class=n-a></a>No</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e427 class=n-a></a>Observation<br class=br>versus<br class=br>WPRT (46 Gy)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e434 class=n-a></a>Primary:<br class=br>Locoregional<br class=br>recurrence and<br class=br>death<br class=br><br class=br>Secondary:<br class=br>Treatment-<br class=br>related morbidity<br class=br>and survival<br class=br>after relapse</td><td align=left colspan=2 rowspan=1 valign=top><a name=d9063e456 class=n-a></a>-5-year locoregional recurrence: 14% obs versus 4%<br class=br>WPRT (<i>P</i> &lt;0.001)<br class=br>-5-year OS: 85% obs versus 81% WPRT (<i>P</i> = 0.31)<br class=br>-Cancer-related death: 6% obs versus 9% WPRT<br class=br>(<i>P</i> = 0.37)<br class=br>-Treatment-related complications: 6% obs versus<br class=br>25% WPRT (<i>P</i> &lt;0.0001)<br class=br>-2-year survival after recurrence: 79% after vaginal<br class=br>versus 21% after pelvic/distant recurrence<br class=br>-15-year follow-up: locoregional recurrence 15.5%<br class=br>obs versus 6% WPRT<sup><a href="#ref-23">23</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e496 class=n-a></a>-Adjuvant RT improves locoregional<br class=br>control, not OS<br class=br>-Limit adjuvant RT to patients age<br class=br>&gt; 60 with G3 and less than half<br class=br>myometrial invasion or any grade<br class=br>with outer half myometrial invasion<br class=br>-Avoid adjuvant RT if age &lt; 60 or<br class=br>G2 with superficial invasion (risk<br class=br>locoregional recurrence &lt; 5%)<br class=br>-15-year follow-up study: confirms.<br class=br>Limit adjuvant pelvic RT to HIR<br class=br>cohort<sup><a href="#ref-23">23</a></sup></td></tr><tr><a name=d9063e527 class=n-a></a><td align=left colspan=1 rowspan=6 valign=top><a name=d9063e529 class=n-a></a>GOG 99<br class=br><br class=br>1987–1995<br class=br><br class=br>N = 392<br class=br><br class=br>Keys <i>et al</i>. (2004)<sup><a href="#ref-19">19</a></sup></td><td align=left colspan=2 rowspan=6 valign=top><a name=d9063e548 class=n-a></a>“Intermediate<br class=br>risk:”<br class=br><br class=br>IB<br class=br>IC<br class=br>II (occult)<sup><a href="#fn1">a</a></sup></td><td align=left colspan=1 rowspan=6 valign=top><a name=d9063e563 class=n-a></a>Yes</td><td align=left colspan=1 rowspan=6 valign=top><a name=d9063e566 class=n-a></a>Observation<br class=br>versus<br class=br>WPRT (50.4 Gy)</td><td align=left colspan=1 rowspan=6 valign=top><a name=d9063e573 class=n-a></a>Primary:<br class=br>Toxicity, date<br class=br>and location of<br class=br>recurrence, OS</td><td align=left colspan=2 rowspan=1 valign=top><a name=d9063e583 class=n-a></a>-Authors defined a HIR group by age and number of<br class=br>RFs:<br class=br><br class=br>RF: grade 2–3, LVSI, and outer 1/3<br class=br></td><td align=left colspan=1 rowspan=6 valign=top><a name=d9063e592 class=n-a></a>-Adjuvant radiation decreases risk of<br class=br>recurrence, but not OS<br class=br>-Limit adjuvant pelvic radiation to<br class=br>patients who fit HIR group</td></tr><tr><a name=d9063e602 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e604 class=n-a></a>Age</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e607 class=n-a></a># RF</td></tr><tr><a name=d9063e611 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e613 class=n-a></a>&lt;50</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e616 class=n-a></a>3</td></tr><tr><a name=d9063e620 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e622 class=n-a></a>50–69</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e625 class=n-a></a>2</td></tr><tr><a name=d9063e630 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e632 class=n-a></a>&gt;70</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e635 class=n-a></a>1</td></tr><tr><a name=d9063e639 class=n-a></a><td align=left colspan=2 rowspan=1 valign=top><a name=d9063e641 class=n-a></a>In all patients:<br class=br>-2-year cumulative incidence of recurrence: 12%<br class=br>obs versus 3% WPRT (RH: 0.42, <i>P</i> = 0.007)<br class=br>-18 versus 3 vaginal recurrences<br class=br>-OS: 86% obs versus 92% WPRT (RH: 0.86,<br class=br><i>P</i> = 0.557)<br class=br>In the HIR group:<br class=br>-2-year recurrence: 26% obs versus 6% WPRT</td></tr><tr><a name=d9063e665 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e667 class=n-a></a>PORTEC-2<br class=br><br class=br>2002–2006<br class=br><br class=br>N = 427<br class=br><br class=br>Nout <i>et al</i>. (2010)<sup><a href="#ref-27">27</a></sup></td><td align=left colspan=2 rowspan=1 valign=top><a name=d9063e686 class=n-a></a>Age &gt; 60<br class=br>IB G3<br class=br>IC G1 or 2<sup><a href="#fn1">a</a></sup><br class=br>IIA (any age,<br class=br>exclude G3<br class=br>with outer half<br class=br>invasion)<br class=br><br class=br>Excluded S/CC</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e708 class=n-a></a>No</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e711 class=n-a></a>EBRT (46 Gy in 23 fx)<br class=br>versus<br class=br>VCB (21 Gy HDR in 3<br class=br>fx or 30 Gy LDR)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e720 class=n-a></a>Non-inferiority<br class=br>trial<br class=br><br class=br>Primary:<br class=br>Vaginal<br class=br>recurrence</td><td align=left colspan=2 rowspan=1 valign=top><a name=d9063e733 class=n-a></a>-5-year vaginal recurrence rate: 1.8% VCB versus<br class=br>1.6% EBRT (HR 0.78, 95% CI 0.17–3.49, <i>P</i> = 0.74)<br class=br>-5-year locoregional relapse: 5.1% VCB versus 2.1%<br class=br>EBRT (HR 2.08, 95% CI 0.71–6.09, <i>P</i> = 0.17)<br class=br>-OS: 84.8% VCB versus 79.6% EBRT (HR 1.17, 95%<br class=br>CI 0.69–1.98; <i>P</i> = 0.67)<br class=br>-Rates grade 1–2 gastrointestinal toxicity: 12.6%<br class=br>VCB versus 53.8% WPRT</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e760 class=n-a></a>-VCB is non-inferior to WPRT in this<br class=br>HIR group, with fewer gastrointestinal<br class=br>toxic effects<br class=br>-Of note, LVSI not considered</td></tr><tr><a name=d9063e770 class=n-a></a><td align=left colspan=1 rowspan=6 valign=top><a name=d9063e772 class=n-a></a>GOG 249<br class=br><br class=br>2009–2013<br class=br><br class=br>N = 601<br class=br><br class=br>Randall <i>et al</i>.<br class=br>(2019)<sup><a href="#ref-24">24</a></sup></td><td align=left colspan=2 rowspan=1 valign=top><a name=d9063e793 class=n-a></a>I with HIR<br class=br>criteria:<br class=br>RF: Outer 1/2,<br class=br>Grade 2 or 3,<br class=br>LVSI</td><td align=left colspan=1 rowspan=6 valign=top><a name=d9063e804 class=n-a></a>Optional:<br class=br>89%<br class=br>assessed<br class=br><br class=br>If not<br class=br>assessed,<br class=br>required<br class=br>imaging<br class=br>(CT or<br class=br>MRI) to rule out<br class=br>enlarged<br class=br>lymph<br class=br>nodes</td><td align=left colspan=1 rowspan=6 valign=top><a name=d9063e831 class=n-a></a>Pelvic RT (4 field<br class=br>or IMRT, 45 to 40.5<br class=br>Gy over 5–6 weeks)<br class=br>Additional VCB<br class=br>optional for S/CC<br class=br>or II)<br class=br>versus<br class=br>VCB (HDR 6–7 Gy<br class=br>at 0.5 cm depth x 3<br class=br>fx, HDR 10–10.5 Gy<br class=br>at vaginal surface<br class=br>×3 fx, or 6 Gy at<br class=br>vaginal surface × 5<br class=br>fx or LDR 65–70 Gy<br class=br>at vaginal surface in<br class=br>1–2 fx), followed by<br class=br>carboplatin AUC 6/<br class=br>paclitaxel 175 mg/m<sup>2</sup><br class=br>Q 21 days × 3 cycles<br class=br>(VCB/C)</td><td align=left colspan=1 rowspan=6 valign=top><a name=d9063e877 class=n-a></a>Primary:<br class=br>RFS<br class=br><br class=br>Secondary:<br class=br>OS, patterns of<br class=br>failure, toxicity</td><td align=left colspan=2 rowspan=6 valign=top><a name=d9063e890 class=n-a></a>-60-month RFS: 0.76 RT (95% CI 0.70–0.81) versus<br class=br>0.76 VCB/C (95% CI 0.70–0.81)<br class=br>-60-month OS: 0.87 RT (95% CI 0.83–0.91) versus<br class=br>0.85 VCB/C (95% CI 0.81–0.90)<br class=br>-No difference in vaginal or distant failures<br class=br>-5-year pelvic and para-aortic nodal failures: 9%<br class=br>VCB/C versus 4% RT, HR 0.47<br class=br>-5-year vaginal recurrence: 2.5% versus 2.5%<br class=br>-5-year distant recurrence: 18% versus 18%<br class=br>-Toxicity:<br class=br>&gt; Grade 3 acute toxicity: 11% RT versus 64% VCB/C<br class=br>&gt; Grade 3 late toxicity: 13% RT versus 12% VCB/C<br class=br>-At 11 weeks, VCB/C arm had 3.7 points lower<br class=br>(98.3% CI -5.9–1.6, <i>P</i> &lt;0.001) on FACIT fatigue<br class=br>subscale score than RT arm. RT arm returned to<br class=br>baseline at 11 weeks and VCB/C arm returned to<br class=br>baseline at 8 months<br class=br>-VCB/C arm reported more neurotoxicity than RT arm,<br class=br>however returned to baseline at 14 months</td><td align=left colspan=1 rowspan=6 valign=top><a name=d9063e935 class=n-a></a>-VCB/C did not improve RFS or OS<br class=br>compared with RT<br class=br>-In subgroup analysis (including<br class=br>serous and clear cell), VCB/C did not<br class=br>improve RFS or OS<br class=br>-Pelvic and para-aortic nodal failures<br class=br>more common in VCB/C<br class=br>-Acute mild/moderate toxicities<br class=br>greater in VCB/C arm, while late<br class=br>toxicities similar versus RT<br class=br>-Pelvic radiation preferred for<br class=br>high-risk, early-stage endometrial<br class=br>carcinoma</td></tr><tr><a name=d9063e965 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e967 class=n-a></a>Age</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e970 class=n-a></a># RF</td></tr><tr><a name=d9063e974 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e976 class=n-a></a>&lt;50</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e979 class=n-a></a>3</td></tr><tr><a name=d9063e984 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e986 class=n-a></a>50–69</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e989 class=n-a></a>2</td></tr><tr><a name=d9063e993 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e995 class=n-a></a>&gt;70</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e998 class=n-a></a>1</td></tr><tr><a name=d9063e1002 class=n-a></a><td align=left colspan=2 rowspan=1 valign=top><a name=d9063e1004 class=n-a></a>II<br class=br>I–II serous<br class=br>or clear cell<br class=br>with negative<br class=br>washings<br class=br>(15% serous,<br class=br>5% CC)</td></tr><tr><a name=d9063e1021 class=n-a></a><td align=left colspan=8 rowspan=1 valign=top><a name=d9063e1023 class=n-a></a><b>Locally advanced</b></td></tr><tr><a name=d9063e1028 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1030 class=n-a></a>GOG 122<br class=br><br class=br>1992–2000<br class=br><br class=br>N = 396<br class=br><br class=br>Randall <i>et al</i>.<br class=br>(2006)<sup><a href="#ref-6">6</a></sup></td><td align=left colspan=2 rowspan=1 valign=top><a name=d9063e1051 class=n-a></a>III/IV (post-<br class=br>op residual<br class=br>disease<br class=br>&lt;2 cm)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1060 class=n-a></a>Optional:<br class=br>86%<br class=br>assessed</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1067 class=n-a></a>WART (30 Gy in 20 fx,<br class=br>with a 15-Gy boost)<br class=br>versus<br class=br>doxorubicin 60 mg/m<sup>2</sup><br class=br>and cisplatin 50 mg/m<sup>2</sup><br class=br>Q 3 weeks × 7 cycles,<br class=br>followed by 1 cycle of<br class=br>cisplatin (AP)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1089 class=n-a></a>Primary:<br class=br>PFS<br class=br><br class=br>Secondary:<br class=br>OS</td><td align=left colspan=2 rowspan=1 valign=top><a name=d9063e1100 class=n-a></a>Stage-adjusted progression: HR 0.71, 95% CI 0.55 to<br class=br>0.91; <i>P</i> &lt;0.01<br class=br>Local recurrence: 13% WART versus 18% AP<br class=br>Distant recurrence: 38% WART versus 32% AP<br class=br>5-year stage-adjusted disease-free survival: 50% CT<br class=br>versus 38% WART<br class=br>5-year stage-adjusted OS: 55% AP versus 42%<br class=br>WART</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1121 class=n-a></a>-Chemotherapy improved PFS and<br class=br>OS compared with WART</td></tr><tr><a name=d9063e1127 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1129 class=n-a></a>PORTEC-3<br class=br><br class=br>2006–2013<br class=br><br class=br>N = 660<br class=br><br class=br>de Boer <i>et al</i>.<br class=br>(2018)<sup><a href="#ref-26">26</a></sup></td><td align=left colspan=2 rowspan=1 valign=top><a name=d9063e1150 class=n-a></a>IA G3 with LVSI<br class=br><br class=br>IB G3<br class=br><br class=br>II<br class=br>III<br class=br><br class=br>I–III S or CC<br class=br>(IA S or CC<br class=br>required<br class=br>to have<br class=br>myometrial<br class=br>invasion)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1175 class=n-a></a>Optional:<br class=br>58%<br class=br>assessed</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1182 class=n-a></a>Pelvic RT (48.6 Gy in<br class=br>1.8 Gy fx)<br class=br>versus<br class=br>combination<br class=br>chemotherapy and<br class=br>radiation (CTRT)<br class=br>(cisplatin 50 mg/m<sup>2</sup><br class=br>weeks 1 and 4 of<br class=br>RT, followed by<br class=br>carboplatin AUC 5<br class=br>and paclitaxel 175<br class=br>mg/m<sup>2</sup> Q 3 weeks × 4<br class=br>cycles)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1216 class=n-a></a>Primary:<br class=br>OS and FFS</td><td align=left colspan=2 rowspan=1 valign=top><a name=d9063e1222 class=n-a></a>-5-year OS: 81.8% CTRT versus 76.7% RT (HR 0.76,<br class=br>95% CI 0.54–1.06; <i>P</i> = 0.11)<br class=br>-5-year FFS: 75.5% CTRT versus 68.8% RT (HR 0.71,<br class=br>95% CI 0.53–0.95; <i>P</i> = 0.022)<br class=br>&gt; Grade 3 adverse events: 60% CTRT versus 12%<br class=br>RT<br class=br><br class=br>Subgroup analysis of stage III patients:<br class=br>-5-year FFS 69.3% CTRT versus 58% RT (HR 0.66,<br class=br>95% CI 0.45–0.97)<br class=br>-5-year OS 78.7% CTRT versus 69.8% RT (HR 0.71,<br class=br>95% CI 0.45–1.11)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1254 class=n-a></a>-CTRT did not improve OS, although<br class=br>it did increase FFS<br class=br>-Subgroup analysis of stage III:<br class=br>improved 5-year FFS (HR 0.66) and<br class=br>trend toward improved OS</td></tr><tr><a name=d9063e1267 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1269 class=n-a></a>GOG 258<br class=br><br class=br>2009–2014<br class=br><br class=br>N = 733<br class=br><br class=br>Matei <i>et al</i>. (2017)<br class=br>(abstract)<sup><a href="#ref-25">25</a></sup></td><td align=left colspan=2 rowspan=1 valign=top><a name=d9063e1290 class=n-a></a>III–IVA (&lt;2 cm<br class=br>residual disease)<br class=br>I–II S/CC<br class=br>with positive<br class=br>washings</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1301 class=n-a></a>Optional:<br class=br>(% N/A)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1306 class=n-a></a>Cisplatin 50 mg/m<sup>2</sup><br class=br>intravenous D1 and<br class=br>D29 plus volume-<br class=br>directed RT (45 Gy<br class=br>± brachytherapy)<br class=br>followed by<br class=br>carboplatin AUC 5/<br class=br>paclitaxel 175 mg/m<sup>2</sup><br class=br>Q 21 days × 4 cycles<br class=br>with G-CSF support<br class=br>(CRT)<br class=br>versus<br class=br>Carboplatin AUC 6/<br class=br>Paclitaxel 175 mg/m<sup>2</sup><br class=br>Q 21 days × 6 cycles<br class=br>(CT)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1347 class=n-a></a>Primary:<br class=br>RFS<br class=br>Secondary:<br class=br>survival, toxicity,<br class=br>quality of life</td><td align=left colspan=2 rowspan=1 valign=top><a name=d9063e1359 class=n-a></a>-Vaginal recurrence: 3% CRT versus 7% CT (HR = 0.36,<br class=br>95% CI 0.16–0.82)<br class=br>-Pelvic and para-aortic node recurrence: 10% CRT<br class=br>versus 21% CT (HR 4.2, 95% CI 0.28–0.66)<br class=br>-Distant recurrence: 28% CRT versus 21% CT, HR<br class=br>1.36, 95% CI 1–1.86)<br class=br>-6-year recurrence-free survival: 35.7% CRT versus<br class=br>38.0% (HR 0.9, 95% CI 0.74–1.1)<br class=br>&gt; Grade 3 toxicity: 58% CRT versus 63% CT<br class=br>-Survival and quality of life endpoints not yet reported</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1381 class=n-a></a>-Chemoradiation did not improve<br class=br>RFS compared with chemotherapy<br class=br>(HR = 0.9, 95% CI 0.74–1.1)<br class=br>-More acute toxicities in CRT versus<br class=br>CT<br class=br>-Fewer vaginal, pelvic, and para-<br class=br>aortic failures in CRT versus CT<br class=br>-Distant recurrences more common<br class=br>in CRT than CT</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d9063e1406 class=n-a></a><p id=fn1> <sup>a</sup>1998 FIGO (International Federation of Gynaecology and Obstetrics) surgical staging: IA: tumor limited to endometrium, IB: tumor invasion less than one half of the myometrium, IC: tumor invasion more than half of the myometrium. II: cervical involvement (included endocervical glandular involvement and cervical stromal invasion).</p><p id=fn2> <sup>b</sup>Grade 1 (G1) ≤ 5% non-squamous or non-morular solid growth pattern; grade 2 (G2): 6–50% non-squamous or non-morular solid growth pattern; and grade 3 (G3): &gt;50% non-squamous or non-morular solid growth pattern.</p><p id=d9063e1420>AP, doxorubicin/cisplatin; AUC, area under the curve; CC, clear cell; CI, confidence interval; CRT, conformal radiation therapy; CT, computed tomography; CTRT, chemotherapy and radiation therapy; EBRT, external beam radiation therapy; FACIT, Functional Assessment of Chronic Illness Therapy; FFS, failure-free survival; fx, fraction; GOG, Gynecologic Oncology Group; Gy, gray; obs, observation; HDR, high-dose radiation therapy; HIR, high-intermediate risk; HR, hazard ratio; IMRT, intensity-modulated radiation therapy; LDR, low-dose radiation therapy; LN, lymph node; LVSI, lymphovascular space invasion; MRI, magnetic resonance imaging; N/A, not available; OS, overall survival; PFS, progression-free survival; PORTEC, Post-Operative Radiation Therapy in Endometrial Carcinoma; Q, every; RF, risk factor; RFS, recurrence-free survival; RH, relative hazard; RT, radiation therapy; S, serous; VCB, vaginal cuff brachytherapy; WART, whole abdominal radiation therapy; WPRT, whole pelvic radiation therapy.</p></div></div></div><div class=section><a name=d9063e1426 class=n-a></a><h3 class=section-title>Stage I and II endometrioid endometrial cancers</h3><p class="" id=d9063e1431>Certain subgroups of early-stage endometrial cancer have a high risk of recurrence. Based on the risk factors identified in GOG 33, a subgroup was identified in GOG 99 as “high-intermediate risk”<sup><a href="#ref-13">13</a></sup>. This cohort accounted for two thirds of recurrences and cancer-related deaths. From these studies, the GOG 249 investigators identified a population of high-risk, early-stage endometrial cancer patients who may benefit from aggressive adjuvant therapy<sup><a href="#ref-24">24</a></sup>. Investigators compared vaginal cuff brachytherapy combined with chemotherapy to pelvic radiation. This was the first GOG study to include intensity-modulated radiation therapy. After a median follow-up of 53 months, they found that chemoradiation did not improve progression-free survival (PFS) and patients receiving chemotherapy experienced more adverse events. There were no differences in vaginal or distant failure rates; however, pelvic and para-aortic nodal failures were more common among patients who received vaginal cuff brachytherapy with chemotherapy. Of note, a subset analysis of patients with serous or clear cell tumors did not find a benefit in PFS or OS with vaginal cuff brachytherapy combined with chemotherapy.</p><p class="" id=d9063e1442>The PORTEC 3 trial, discussed in further detail below, also included high-risk, early-stage endometrioid endometrial cancers (stage I grade 3 endometrioid cancers with deep myometrial invasion or LVSI and stage II endometrioid cancers). This study compared chemoradiation to whole pelvic radiation and did not find significant improvement in failure-free survival (FFS) (hazard ratio [HR] 0.79, 95% confidence interval [CI] 0.47–1.33) or OS (HR 0.77, 95% CI 0.49–1.21) to justify the addition of chemotherapy in stage I or II endometrioid cancers<sup><a href="#ref-26">26</a></sup>.</p><p class="" id=d9063e1449>Given increased toxicity without PFS or OS benefit, we would recommend against chemotherapy for high-risk stage I and II endometrioid endometrial cancers. Radiation should be considered for local control. Given the results of the PORTEC trials<sup><a href="#ref-22">22</a>,<a href="#ref-23">23</a>,<a href="#ref-26">26</a>,<a href="#ref-27">27</a></sup>, it would be reasonable to offer external beam radiation therapy (EBRT) for grade 3 endometrioid cancers with deep myometrial invasion or LVSI or both. Other high-intermediate risk endometrioid cancers can be treated with adjuvant vaginal cuff brachytherapy<sup><a href="#ref-22">22</a>,<a href="#ref-23">23</a>,<a href="#ref-27">27</a></sup>.</p></div><div class=section><a name=d9063e1476 class=n-a></a><h3 class=section-title>Advanced endometrioid endometrial cancers</h3><p class="" id=d9063e1481>Defining the optimal post-operative adjuvant treatment for advanced endometrial cancer remains challenging. There is increased risk of distant failure in patients who receive radiation alone and increased pelvic failures in patients who receive chemotherapy alone. GOG 122 showed a PFS and OS benefit with chemotherapy (doxorubicin 60 mg/m<sup>2</sup> and cisplatin 50 mg/m<sup>2</sup> every three weeks for seven cycles, followed by one cycle of cisplatin) compared with whole abdomen radiation therapy in patients with stage III to IVA with less than 2 cm post-operative residual disease<sup><a href="#ref-6">6</a></sup>.</p><p class="" id=d9063e1494>Given the concern for increased pelvic relapse with adjuvant chemotherapy alone in high-risk endometrial cancer, the phase II RTOG-9708 trial assessed the toxicity of adjuvant combined chemoradiation and chemotherapy in grade 2 or 3 endometrial adenocarcinoma with outer one half myometrial invasion, cervical stromal invasion, or pelvic-confined extrauterine disease<sup><a href="#ref-28">28</a></sup>. The trial showed promising locoregional control (4-year disease-free survival 85% and OS 81%) with adjuvant cisplatin 50 mg/m<sup>2</sup> intravenously at days 1 and 29 plus volume-directed radiation therapy (45 Gy ± brachytherapy) followed by paclitaxel 175 mg/m<sup>2</sup> and carboplatin area under the curve (AUC) 5 every 21 days for four cycles. Given their success and the theoretical benefit of obtaining both local and distant control with combined chemotherapy and radiation, GOG 258 and PORTEC 3 used similar regimens in their experimental arms. Since the last review, the results of GOG 258 have been presented and published in abstract form, and the results of PORTEC 3 have been published<sup><a href="#ref-25">25</a>,<a href="#ref-26">26</a></sup>.</p><p class="" id=d9063e1514>GOG 258 compared chemoradiation followed by four cycles of paclitaxel/carboplatin to six cycles of paclitaxel/carboplatin alone (<a href="#T1">Table 1</a>)<sup><a href="#ref-25">25</a></sup>. The combined arm had fewer vaginal, pelvic, and para-aortic recurrences and more distant recurrences and toxicity; however, there was no improvement in PFS or OS. PORTEC 3 compared chemoradiation plus chemotherapy with whole pelvic radiation alone in patients with high-risk stage I to III endometrial cancer (<a href="#T1">Table 1</a>)<sup><a href="#ref-26">26</a></sup>. The investigators found that the addition of chemotherapy improved FFS but did not result in a significant improvement in OS. A subgroup analysis of stage III patients showed the greatest FFS advantage (HR 0.66, 95% CI 0.45–0.97) with a non-significant trend toward improved OS (HR 0.71, 95% CI 0.45–1.11). The results of these large phase III studies did not identify a clear best option for adjuvant therapy; however, it may be extrapolated that adjuvant chemotherapy is most important for stage III patients.</p><p class="" id=d9063e1531>In summary, in regard to the latest studies, adjuvant chemotherapy likely has the most benefit in stage III and IV patients. Radiation therapy can be considered for local control. The NCCN recommends systemic therapy with or without vaginal brachytherapy or EBRT with or without vaginal brachytherapy with or without systemic therapy for adjuvant therapy of advanced-stage endometrial cancer<sup><a href="#ref-29">29</a></sup>.</p></div><div class=section><a name=d9063e1540 class=n-a></a><h3 class=section-title>Serous and clear cell endometrial cancers</h3><p class="" id=d9063e1545>Uterine serous carcinoma is an aggressive and less common type of endometrial cancer, comprising only 3 to 10% of endometrial cancers but accounting for 39% of endometrial cancer deaths<sup><a href="#ref-30">30</a></sup>. Its molecular profile differs from that of type 1 endometrioid histologies; it has a high rate (90%) of TP53 alterations and about a 30% rate of HER2/neu alterations<sup><a href="#ref-31">31</a>,<a href="#ref-32">32</a></sup>. High rates of extrauterine spread are common at presentation; 40 to 70% of cases of metastatic disease may be apparent only with comprehensive surgical staging<sup><a href="#ref-33">33</a></sup>. The GOG typically requires that tumors classified as serous have more than 50% serous histology if a tumor is of mixed cell type<sup><a href="#ref-34">34</a></sup>. However, a study by Boruta <i>et al</i>. demonstrated that even serous tumors with a minor component (&lt;10%) had poorer prognosis compared with grade 3 pure endometrioid histology<sup><a href="#ref-35">35</a></sup>.</p><p class="" id=d9063e1575>Clear cell endometrial cancers represent about 4% of all uterine tumors and similarly have high rates of occult metastases (40%) and poor survival (40% 5-year survival regardless of stage)<sup><a href="#ref-36">36</a></sup>. About 30 to 40% of clear cell carcinomas have TP53 alterations<sup><a href="#ref-32">32</a></sup>. They are intermediate in microsatellite instability (MSI) frequency (15%) and phosphatase and tensin homolog (PTEN) alterations (30%) compared with endometrioid (20 to 40% MSI and 10% PTEN alterations) and serous (&lt;5% MSI and 35 to 50% PTEN alterations) carcinomas<sup><a href="#ref-32">32</a></sup>. The literature to support definitive recommendations for adjuvant treatment for serous and clear cell uterine cancers is limited because they are relatively rare. Patients with serous and clear cell histology are often included in heterogeneous trials of high-risk uterine cancers. In trials discussed above, GOG 249 included patients with stage I or II serous and clear cell uterine cancer with negative cytology; GOG 258 included stages I or II with positive cytology and stages III or IV; and PORTEC 3 included patients with stages I to III serous or clear cell cancers. It is difficult to draw conclusions regarding treatment since these histologies usually compose less than 20% of the cohort<sup><a href="#ref-6">6</a>,<a href="#ref-24">24</a>,<a href="#ref-26">26</a></sup>. Because of their aggressive nature, uterine serous and clear cell carcinomas with any myometrial invasion are often treated with adjuvant chemotherapy. The NCCN guidelines recommend chemotherapy with or without vaginal brachytherapy for IA serous or clear cell endometrial cancers, although they offer observation or EBRT as acceptable alternatives. For IB (or greater) disease, they recommend chemotherapy with or without EBRT with or without vaginal brachytherapy<sup><a href="#ref-29">29</a></sup>.</p></div><div class=section><a name=d9063e1605 class=n-a></a><h3 class=section-title>HER2/neu-positive serous endometrial cancers</h3><p class="" id=d9063e1610>Fader <i>et al</i>. published their randomized phase II trial of paclitaxel and carboplatin with or without trastuzumab in primary stage III or IV or recurrent HER2/neu-positive uterine serous carcinomas<sup><a href="#ref-37">37</a></sup>. They randomly assigned 61 patients and found a median PFS of 12.6 months in the paclitaxel, carboplatin, and trastuzumab arm versus 8.0 months in the paclitaxel and carboplatin alone arm. In the 41 patients with primary advanced-stage disease, the PFS was 17.9 months in the trastuzumab arm versus 9.3 months in the paclitaxel/carboplatin alone arm. In the 17 patients with recurrent disease, PFS was 9.2 months in the trastuzumab arm versus 6 months in the paclitaxel/carboplatin arm. There is a suggestion of an OS advantage in the trastuzumab arm, and the greatest benefit is in the up-front setting, but the data are not yet mature. These preliminary findings are of considerable interest and suggest benefit for up-front HER2/neu tumor profiling to guide adjuvant therapy of this difficult disease.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d9063e1624>Treatment of recurrent endometrial cancers</h2><p class="" id=d9063e1627>Systemic recurrence of endometrial cancer is generally considered incurable and is associated with a poor prognosis. A variety of GOG studies have looked at single agents (etoposide, paclitaxel, dactinomycin, liposomal doxorubicin, pyrazoloacridine, topotecan, oxaliplatin, irofulven, flavopiridol, and bevacizumab) and alternating courses of megestrol acetate and tamoxifen in recurrent endometrial cancer, and response rates range from 0 to 31% and 6-month PFS rates from 0 to 43%<sup><a href="#ref-38">38</a>–<a href="#ref-48">48</a></sup>. Hormonal therapy is an appealing option in recurrent endometrial cancer given that many endometrial cancers are hormonally driven and the relative lack of toxicity with hormonal therapy. However, response rates and PFS have been disappointing. Given cross-regulation between the estrogen receptor (ER) and PI3K/AKT/mTOR pathway and recent success of combination everolimus and an aromatase inhibitor in aromatase-refractory breast cancer, Slomovitz <i>et al</i>. hypothesized that combining everolimus and letrozole would result in improved response rates and PFS<sup><a href="#ref-49">49</a>,<a href="#ref-50">50</a></sup>. In their phase II study, they found a clinical benefit rate of 40%, and 23% of patients obtained a complete response<sup><a href="#ref-49">49</a></sup>. The authors found that their oral regimen of everolimus 10 mg daily with letrozole 2.5 mg daily was well tolerated, and no patients discontinued the study because of toxicity. Metformin use and CTNNB1 mutations were associated with increased response rates, PFS, and OS, although these findings were not statistically significant. Of note, none of the patients (n = 7) with serous histology had a response. Patients with ER-positive and progesterone receptor (PR)-positive tumors had higher response rates than receptor-negative tumors, although 33% of ER-negative patients and 25% of PR-negative patients had responses. Given these promising results, the investigators evaluated this combined regimen compared with alternating megestrol acetate and tamoxifen in GOG 3007, which was recently published as an abstract<sup><a href="#ref-51">51</a></sup>. They reported a 24% response rate in the everolimus/letrozole arm (PFS 6.4 months and OS 20.0 months) and a 22% response rate in the progestin/tamoxifen arm (PFS 3.8 months and OS 16.6 months). Hormonal combined therapies remain appealing options for recurrent endometrial cancer, and biomarkers are needed to better predict which patients will benefit.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d9063e1658>Understanding the molecular biology of endometrial cancer</h2><p class="" id=d9063e1661>Advances in our classification of endometrial cancer with molecular profiling may enable us to better stratify risk and recommended therapy. MSI and polymerase-ε (POLE) lead to neoantigens, fragments of proteins expressed by tumor cells that may sensitize the immune system<sup><a href="#ref-52">52</a></sup>. The molecular profile of a tumor may better define its prognosis and response to therapy than histology and stage alone. Talhouk <i>et al</i>.<sup><a href="#ref-53">53</a>–<a href="#ref-55">55</a></sup>, The Cancer Genome Atlas Collaborative (TCGA)<sup><a href="#ref-53">53</a>–<a href="#ref-55">55</a></sup>, and the GOG 210 investigators<sup><a href="#ref-53">53</a>–<a href="#ref-55">55</a></sup> have developed different molecular classification schema to better stratify patient risk.</p><p class="" id=d9063e1692>The TCGA project determined four molecularly defined subgroups of endometrial cancer, which yielded excellent prognostic results<sup><a href="#ref-53">53</a></sup>. However, the methods required for classification are currently quite expensive and require special handling of the tissue, limiting applicability. Talhouk <i>et al</i>. developed a more pragmatic method, the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) classification, to identify molecularly distinct subgroups with a prognostic signature similar to that of the TCGA classification scheme<sup><a href="#ref-54">54</a>,<a href="#ref-56">56</a></sup>. The four groups were MMR-deficient (MMR-D), POLE exonuclease domain mutations (POLE EDMs), p53 abnormal, and p53 wild-type. They assessed tumors in a step-wise fashion. The first assessment was based on MMR status, and MMR-D tumors were classified as MMR-D and MMR intact tumors were tested for POLE mutations. POLE mutants were classified as POLE EDM, and POLE wild-type tumors were assessed for p53 status. MMR intact, POLE wild-type tumors were classified as p53 wild-type or p53 abnormal (null/missense mutations). They validated the ProMisE classifier in a large confirmation cohort series and found that POLE EDMs had the best prognosis and p53 mutants the worst. The ProMisE classification system improved outcome prediction compared with European Society for Medical Oncology risk stratification, detecting those at risk for Lynch syndrome and potentially guiding clinical management<sup><a href="#ref-56">56</a></sup>.</p><p class="" id=d9063e1713>GOG 210, an NRG Oncology/GOG study of the molecular classification for risk prediction in endometrioid endometrial cancer, was published in <i>Gynecologic Oncology</i> in August 2017<sup><a href="#ref-55">55</a></sup>. The investigators sought to develop a classification system for endometrioid endometrial cancers, the most common and potentially challenging endometrial cancer histology to classify. They assessed tumors for mismatch repair (MMR) defects (MSI, MMR IHC, and MLH1 methylation), POLE mutations, and loss of heterozygosity. Using four classifications (MMR deficient, copy number altered (CNA), copy number stable, and POLE mutant), they were able to stratify patients by PFS and OS. Their classification system remained statistically significantly related to clinical outcomes in multivariable analyses. CNA had the worst PFS and cancer-specific survival, whereas the POLE group had the best outcomes. The authors advocate prospective validation of this system and recommend that clinicians consider using it to universally screen for Lynch syndrome and identify additional prognostic information to guide treatment decisions.</p><p class="" id=d9063e1723>Biomarkers and molecular alterations are increasingly being used to guide systemic therapy in the recurrent setting. <a href="#T2">Table 2</a> outlines common biomarkers in endometrial cancer, noting differences between type I (grade 1 or 2 endometrioid) and type II (grade 3 endometrioid, serous, clear cell, and carcinosarcoma) endometrial cancers as well as potential targeted therapies (<a href="#T2">Table 2</a>).</p><a name=T2 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 2. Expression of biomarkers in type 1 and type 2 endometrial cancer.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d9063e1744 class=n-a></a><thead><a name=d9063e1746 class=n-a></a><tr><a name=d9063e1748 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d9063e1750 class=n-a></a>Target</th><th align=left colspan=1 rowspan=1 valign=top><a name=d9063e1753 class=n-a></a>Function</th><th align=left colspan=1 rowspan=1 valign=top><a name=d9063e1756 class=n-a></a>Change</th><th align=left colspan=1 rowspan=1 valign=top><a name=d9063e1759 class=n-a></a>Type 1,<br class=br>percentage</th><th align=left colspan=1 rowspan=1 valign=top><a name=d9063e1764 class=n-a></a>Type 2,<br class=br>percentage</th><th align=left colspan=1 rowspan=1 valign=top><a name=d9063e1770 class=n-a></a>Outcome</th><th align=left colspan=1 rowspan=1 valign=top><a name=d9063e1773 class=n-a></a>Potential targeted therapy</th></tr></thead><tbody><a name=d9063e1778 class=n-a></a><tr><a name=d9063e1780 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1782 class=n-a></a><i>HER-2/</i><br class=br><i>neu</i></td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1789 class=n-a></a>Oncogene</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1792 class=n-a></a>Enhanced<br class=br>expression</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1797 class=n-a></a>Rare</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1800 class=n-a></a>18–80</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1804 class=n-a></a>Poor prognosis,<br class=br>aggressive tumor<sup><a href="#ref-57">57</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1812 class=n-a></a>HER2 inhibitors<br class=br>(afatinib<sup><a href="#ref-58">58</a></sup><sup><a href="#tfn1">a</a></sup>, trastuzumab<sup><a href="#ref-37">37</a></sup>, and<br class=br>lapatinib<sup><a href="#ref-59">59</a></sup><sup><a href="#tfn1">a</a></sup>)</td></tr><tr><a name=d9063e1839 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1841 class=n-a></a>ER and<br class=br>PR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1846 class=n-a></a>Transcription<br class=br>factor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1851 class=n-a></a>Enhanced<br class=br>expression</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1856 class=n-a></a>70–73</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1859 class=n-a></a>19–24</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1863 class=n-a></a>Improved overall<br class=br>survival<sup><a href="#ref-60">60</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1871 class=n-a></a>Tamoxifen, megestrol acetate<sup><a href="#ref-38">38</a></sup>,<br class=br>medroxyprogesterone acetate<sup><a href="#ref-61">61</a></sup>,<br class=br>letrozole<sup><a href="#ref-49">49</a>,<a href="#ref-51">51</a></sup></td></tr><tr><a name=d9063e1893 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1895 class=n-a></a><i>p53</i></td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1899 class=n-a></a>Tumor<br class=br>suppressor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1904 class=n-a></a>Mutation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1907 class=n-a></a>5–10</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1910 class=n-a></a>80–90</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1914 class=n-a></a>Poor prognosis<sup><a href="#ref-62">62</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1920 class=n-a></a>Anti-VEGF<br class=br>(bevacizumab)<sup><a href="#ref-63">63</a>–<a href="#ref-66">66</a></sup></td></tr><tr><a name=d9063e1932 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1934 class=n-a></a><i>PIK3CA</i></td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1938 class=n-a></a>Oncogene</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1941 class=n-a></a>Mutation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1944 class=n-a></a>26–90<sup><a href="#ref-53">53</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1950 class=n-a></a>26–36</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1954 class=n-a></a>No association with<br class=br>survival, except exon<br class=br>9 charge-changing<br class=br>mutations associated<br class=br>with worse survival<sup><a href="#ref-67">67</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1968 class=n-a></a>mTOR inhibitor<sup><a href="#ref-68">68</a>,<a href="#ref-69">69</a></sup><br class=br>(everolimus and temsirolimus<sup><a href="#ref-70">70</a></sup>)<br class=br>± letrozole<sup><a href="#ref-49">49</a>,<a href="#ref-51">51</a></sup></td></tr><tr><a name=d9063e1992 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e1994 class=n-a></a> <i>PTEN</i> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2000 class=n-a></a>Tumor<br class=br>suppressor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2005 class=n-a></a>Mutation, deletion,<br class=br>methylation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2010 class=n-a></a>35–55</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2013 class=n-a></a>0–11</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2017 class=n-a></a>Poor prognosis<sup><a href="#ref-71">71</a>–<a href="#ref-73">73</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2026 class=n-a></a>mTOR inhibitor<sup><a href="#ref-68">68</a>,<a href="#ref-69">69</a></sup><br class=br>(everolimus<sup><a href="#ref-74">74</a></sup> and<br class=br>temsirolimus<sup><a href="#tfn1">a</a></sup>), evaluating<br class=br>combination with olaparib<br class=br>(<a target=xrefwindow href="https://clinicaltrials.gov/" id=d9063e2051>ClinicalTrials.gov</a><br class=br>Identifier:<br class=br>NCT02208375)</td></tr><tr><a name=d9063e2060 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2062 class=n-a></a> <i>EZH2</i> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2068 class=n-a></a>Transcription<br class=br>factor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2073 class=n-a></a>Enhanced<br class=br>expression</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2078 class=n-a></a>16</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2081 class=n-a></a>36</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2085 class=n-a></a>Poor prognosis,<br class=br>aggressive tumor<sup><a href="#ref-75">75</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2093 class=n-a></a>EZH2 inhibitor<sup><a href="#tfn1">a</a></sup><br class=br>(EPZ-6438, <a target=xrefwindow href="https://clinicaltrials.gov/" id=d9063e2100>ClinicalTrials.gov</a><br class=br>Identifier:<br class=br>NCT01897571)</td></tr><tr><a name=d9063e2108 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2110 class=n-a></a><i>K-ras</i> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2115 class=n-a></a>Oncogene</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2118 class=n-a></a>Mutation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2121 class=n-a></a>13–26</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2124 class=n-a></a>0–10</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2128 class=n-a></a>Poor prognosis<sup><a href="#ref-76">76</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2134 class=n-a></a>MEK inhibitor<sup><a href="#ref-77">77</a>,<a href="#ref-78">78</a></sup><sup><a href="#tfn1">a</a></sup><br class=br>(trametinib, cobimetinib, and<br class=br>selumetinib<sup><a href="#tfn1">b</a></sup>),<br class=br>GOG-2290 evaluating<br class=br>trametinib ± Akt inhibitor</td></tr><tr><a name=d9063e2160 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2162 class=n-a></a> <i>MLH1</i> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2168 class=n-a></a>DNA repair</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2171 class=n-a></a>Methylation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2174 class=n-a></a>20–35</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2177 class=n-a></a>0–10</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2181 class=n-a></a>No association with<br class=br>survival<sup><a href="#ref-79">79</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2189 class=n-a></a>Checkpoint inhibitor:<br class=br>Pembrolizumab<sup><a href="#ref-52">52</a>,<a href="#ref-80">80</a></sup></td></tr><tr><a name=d9063e2201 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2203 class=n-a></a>PD-L1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2206 class=n-a></a>Ligand for<br class=br>PD-1, immune<br class=br>checkpoint<br class=br>receptor on<br class=br>tumor-infiltrating<br class=br>lymphocytes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2219 class=n-a></a>Expression on tumor<br class=br>cells</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2224 class=n-a></a>14–48<sup><a href="#ref-79">79</a>,<a href="#ref-81">81</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2233 class=n-a></a>33<sup><a href="#ref-82">82</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2240 class=n-a></a>Trend toward<br class=br>improved survival<sup><a href="#ref-83">83</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2248 class=n-a></a>Checkpoint inhibitor:<br class=br>Pembrolizumab<sup><a href="#ref-84">84</a></sup></td></tr><tr><a name=d9063e2257 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2259 class=n-a></a>MSI</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2262 class=n-a></a>Downstream<br class=br>evidence of<br class=br>deficient DNA<br class=br>mismatch repair<br class=br>system</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2273 class=n-a></a>Polymerase chain<br class=br>reaction amplification<br class=br>of specific<br class=br>microsatellite repeats</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2282 class=n-a></a>33–40<sup><a href="#ref-79">79</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2288 class=n-a></a>2<sup><a href="#ref-53">53</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2295 class=n-a></a>No association with<br class=br>survival<sup><a href="#ref-79">79</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d9063e2303 class=n-a></a>Checkpoint inhibitor:<br class=br>Pembrolizumab<sup><a href="#ref-52">52</a>,<a href="#ref-80">80</a></sup></td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d9063e2319 class=n-a></a><p id=tfn1> First five columns adapted from Engelsen <i>et al</i>.<sup><a href="#ref-85">85</a></sup>. <sup>a</sup>Actionability shown in other cancer types<sup><a href="#ref-86">86</a></sup>. <sup>b</sup>Low response rates (6%) shown in <i>k-ras</i> unselected population with selumetinib as single agent<sup><a href="#ref-87">87</a></sup>. ER, estrogen receptor; EZH2, enhancer of zeste homolog 2; <i>HER-2</i>/neu, human epidermal growth factor receptor 2, protoconcogene Neu; <i>K-</i>ras, Kirsten RAt sarcoma virus; MLH1, MutL homolog 1; MSI, microsatellite instability; mTOR, mammalian target of rapamycin; PD-1, programmed death 1; PD-L1, programmed death ligand 1; <i>PIK3CA</i>, phosphatidylinositol 3-kinase catalytic subunit; PR, progesterone receptor; <i>PTEN</i>, phosphatase and tensin homolog; VEGF, vascular endothelial growth factor.</p></div></div></div><p class="" id=d9063e2364>In our practice, we test all primary endometrial cancers with IHC for MMR proteins and, if findings are consistent with Lynch syndrome (absence of staining and no evidence of promoter methylation), proceed to confirmatory testing. In addition, we perform MSI testing if there is a high clinical suspicion for Lynch syndrome even with intact proteins. We perform IHC for HER2/neu status in all serous cancers and confirm overexpression with fluorescence <i>in situ</i> hybridization. We have not yet adapted routine molecular classification; however, we optimistically await further results to guide systemic therapy by molecular class. In the recurrent setting, we recommend molecular profiling, testing for immunotherapy biomarkers (programmed death ligand-1 (PD-L1), MSI, and tumor molecular burden), HER2/neu status in serous cancer, and determining ER and PR status.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d9063e2374>Immunotherapy in endometrial cancer</h2><p class="" id=d9063e2377>Programmed death 1 (PD-1) is an immune checkpoint receptor expressed on tumor-infiltrating T cells that, when activated by PD-L1, blocks T-cell activation and enables immune evasion<sup><a href="#ref-84">84</a>,<a href="#ref-88">88</a>–<a href="#ref-90">90</a></sup>. About one half of endometrial tumors evaluated in KEYNOTE-028, a phase 1b study, were PD-L1–positive<sup><a href="#ref-84">84</a></sup>. In this study, investigators evaluated the safety and efficacy of pembrolizumab, an anti–PD-1 monoclonal antibody, in patients with PD-L1–positive tumors. In this heavily pretreated cohort of women, 24 women were enrolled; three patients (13.0%) achieved a partial response and three patients achieved stable disease (median duration of 24.6 weeks). Over half of the patients developed a treatment-related toxicity, of which fatigue, pruritus, pyrexia, and anorexia were the most common. Pembrolizumab was well tolerated overall and resulted in durable response in a subset of patients; however, there remains a need to better identify biomarkers to predict durable response. In 2017, the US Food and Drug Administration (FDA) approved pembrolizumab for all advanced solid tumors that are MSI-high or MMR-D.</p><p class="" id=d9063e2394>Makker <i>et al</i>. recently published an interim analysis of their phase 2 study of pembrolizumab plus lenvatinib in biomarker-unselected advanced endometrial cancer<sup><a href="#ref-91">91</a></sup>. In the unselected cohort (85% microsatellite stable and 25% PD-L1–positive), 39.6% of patients responded with durable responses (65% had responses greater than 6 months, and median duration of response was not yet achieved)<sup><a href="#ref-91">91</a></sup>. This trial led to FDA breakthrough therapy designation for pembrolizumab with lenvatinib in advanced endometrial cancer. The group has started enrollment for a phase 3 randomized clinical trial of pembrolizumab and lenvatinib versus doxorubicin or paclitaxel. Further research is ongoing to identify a combinatorial approach with other immunotherapies, radiation, or systemic treatment in order to augment the effects of immunotherapy in endometrial cancer.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d9063e2411>Future directions and current clinical trials</h2><p class="" id=d9063e2414>Although there have been great advances in endometrial cancer in the past few years, there remains much left to do as we continue to refine our understanding and treatment of endometrial cancer. Focus will be on better classifying tumors in order to more appropriately enroll patients in clinical trials specific to that profile. We need to identify better biomarkers to guide personalized therapy as well as to explore combinatorial regimens for targeted therapeutics, hormonal therapy, and immunotherapy. Featured actively recruiting trials include a randomized phase III trial in women with endometrial cancer with high-intermediate risk factors to investigate the role of an integrated clinicopathological and molecular risk profile to guide adjuvant therapy (PORTEC 4-a, ClinicalTrials.gov Identifier: NCT03469674); a phase II trial of paclitaxel, carboplatin, and pembrolizumab in measurable advanced or recurrent endometrial cancer (ClinicalTrials.gov Identifier: NCT02549209); a phase II trial of vaginal cuff brachytherapy followed by adjuvant chemotherapy with carboplatin and dose-dense paclitaxel in patients with high-risk endometrial cancer (ClinicalTrials.gov Identifier: NCT03189446); a phase I study of the Wee I kinase inhibitor AZD1775 in combination with radiotherapy and cisplatin in cervical, upper vaginal, and uterine cancers (ClinicalTrials.gov Identifier: NCT03345784); a randomized phase II study comparing single-agent olaparib, single-agent cediranib, or combination cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer (GY012, ClinicalTrials.gov Identifier: NCT03660826); and multiple trials combining checkpoint inhibitors, immunotherapy, tyrosine kinase inhibitors, poly ADP ribose polymerase (PARP) inhibitors, and/or anti-angiogenic inhibitors (TSR042 Garnet study, UC1805, NRG-GY018, AMANDA study, KEYNOTE-077/ECHO-202, KEYNOTE-775, and ROSCAN).</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d9063e1 class=n-a></a><h2 class=main-title id=d9358>Grant information</h2><p>The author(s) declared that no grants were involved in supporting this work.</p></div><div class=back-section><a name=d9063e2421 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d9653>References</h2><div class="section ref-list"><a name=d9063e2421 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d9063e2428 class=n-a></a>Siegel RL, Miller KD, Jemal A: Cancer statistics, 2019. <i>CA Cancer J Clin.</i> 2019; <b>69</b>(1): 7–34. <a target=xrefwindow id=d9063e2436 href="http://www.ncbi.nlm.nih.gov/pubmed/30620402">PubMed Abstract </a> | <a target=xrefwindow id=d9063e2439 href="https://doi.org/10.3322/caac.21551">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d9063e2448 class=n-a></a>Evans T, Sany O, Pearmain P, <i> et al.</i>: Differential trends in the rising incidence of endometrial cancer by type: data from a UK population-based registry from 1994 to 2006. <i>Br J Cancer.</i> 2011; <b>104</b>(9): 1505–10. <a target=xrefwindow id=d9063e2459 href="http://www.ncbi.nlm.nih.gov/pubmed/21522151">PubMed Abstract </a> | <a target=xrefwindow id=d9063e2462 href="https://doi.org/10.1038/bjc.2011.68">Publisher Full Text </a> | <a target=xrefwindow id=d9063e2466 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3101940">Free Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727295274"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9063e2475 class=n-a></a>Tran AQ, Gehrig P: Recent Advances in Endometrial Cancer. <i>F1000Res.</i> 2017; <b>6</b>: 81. <a target=xrefwindow id=d9063e2483 href="http://www.ncbi.nlm.nih.gov/pubmed/28184290">PubMed Abstract </a> | <a target=xrefwindow id=d9063e2486 href="https://doi.org/10.12688/f1000research.10020.1">Publisher Full Text </a> | <a target=xrefwindow id=d9063e2489 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5288678">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727295274">F1000 Recommendation</a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d9063e2502 class=n-a></a>Hogberg T: Adjuvant Chemotherapy in Endometrial Cancer. <i>Int J Gynecol Cancer.</i> 2010; <b>20</b>(Suppl 2): S57–S59. <a target=xrefwindow id=d9063e2510 href="https://doi.org/10.1111/IGC.0b013e3181f749fd">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727273935"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9063e2519 class=n-a></a>Rossi EC, Kowalski LD, Scalici J, <i> et al.</i>: A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. <i>Lancet Oncol.</i> 2017; <b>18</b>(3): 384–92. <a target=xrefwindow id=d9063e2530 href="http://www.ncbi.nlm.nih.gov/pubmed/28159465">PubMed Abstract </a> | <a target=xrefwindow id=d9063e2533 href="https://doi.org/10.1016/S1470-2045(17)30068-2">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727273935">F1000 Recommendation</a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/14006"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9063e2547 class=n-a></a>Randall ME, Filiaci VL, Muss H, <i> et al.</i>: Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. <i>J Clin Oncol.</i> 2006; <b>24</b>(1): 36–44. <a target=xrefwindow id=d9063e2558 href="http://www.ncbi.nlm.nih.gov/pubmed/16330675">PubMed Abstract </a> | <a target=xrefwindow id=d9063e2561 href="https://doi.org/10.1200/JCO.2004.00.7617">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/14006">F1000 Recommendation</a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d9063e2574 class=n-a></a>Abu-Rustum NR, Alektiar K, Iasonos A, <i> et al.</i>: The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center. <i>Gynecol Oncol.</i> 2006; <b>103</b>(2): 714–8. <a target=xrefwindow id=d9063e2585 href="http://www.ncbi.nlm.nih.gov/pubmed/16740298">PubMed Abstract </a> | <a target=xrefwindow id=d9063e2588 href="https://doi.org/10.1016/j.ygyno.2006.03.055">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d9063e2597 class=n-a></a>Cardosi RJ, Cox CS, Hoffman MS: Postoperative neuropathies after major pelvic surgery. <i>Obstet Gynecol.</i> 2002; <b>100</b>(2): 240–4. <a target=xrefwindow id=d9063e2605 href="http://www.ncbi.nlm.nih.gov/pubmed/12151144">PubMed Abstract </a> | <a target=xrefwindow id=d9063e2608 href="https://doi.org/10.1097/00006250-200208000-00007">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727188279"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9063e2617 class=n-a></a>Kang S, Nam JH, Bae DS, <i> et al.</i>: Preoperative assessment of lymph node metastasis in endometrial cancer: A Korean Gynecologic Oncology Group study. <i>Cancer.</i> 2017; <b>123</b>(2): 263–72. <a target=xrefwindow id=d9063e2628 href="http://www.ncbi.nlm.nih.gov/pubmed/28067948">PubMed Abstract </a> | <a target=xrefwindow id=d9063e2631 href="https://doi.org/10.1002/cncr.30349">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727188279">F1000 Recommendation</a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727210752"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9063e2644 class=n-a></a>Hurteau JA: Omitting lymphadenectomy in patients with endometrial cancer. <i>Cancer.</i> 2017; <b>123</b>(2): 197–9. <a target=xrefwindow id=d9063e2652 href="http://www.ncbi.nlm.nih.gov/pubmed/28067947">PubMed Abstract </a> | <a target=xrefwindow id=d9063e2655 href="https://doi.org/10.1002/cncr.30346">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727210752">F1000 Recommendation</a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732345753"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9063e2668 class=n-a></a>Geppert B, Lönnerfors C, Bollino M, <i> et al.</i>: Sentinel lymph node biopsy in endometrial cancer-Feasibility, safety and lymphatic complications. <i>Gynecol Oncol.</i> 2018; <b>148</b>(3): 491–8. <a target=xrefwindow id=d9063e2679 href="http://www.ncbi.nlm.nih.gov/pubmed/29273307">PubMed Abstract </a> | <a target=xrefwindow id=d9063e2682 href="https://doi.org/10.1016/j.ygyno.2017.12.017">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732345753">F1000 Recommendation</a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735842465"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9063e2696 class=n-a></a>Bogani G, Ditto A, Leone Roberti Maggiore U, <i> et al.</i>: Sentinel-lymph-node mapping in endometrial cancer. <i>Lancet Oncol.</i> 2017; <b>18</b>(5): e234. <a target=xrefwindow id=d9063e2707 href="http://www.ncbi.nlm.nih.gov/pubmed/28495280">PubMed Abstract </a> | <a target=xrefwindow id=d9063e2710 href="https://doi.org/10.1016/S1470-2045(17)30247-4">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735842465">F1000 Recommendation</a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d9063e2723 class=n-a></a>Creasman WT, Morrow CP, Bundy BN, <i> et al.</i>: Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. <i>Cancer.</i> 1987; <b>60</b>(8 Suppl): 2035–41. <a target=xrefwindow id=d9063e2734 href="http://www.ncbi.nlm.nih.gov/pubmed/3652025">PubMed Abstract </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731602853"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9063e2743 class=n-a></a>Ducie JA, Eriksson AGZ, Ali N, <i> et al.</i>: Comparison of a sentinel lymph node mapping algorithm and comprehensive lymphadenectomy in the detection of stage IIIC endometrial carcinoma at higher risk for nodal disease. <i>Gynecol Oncol.</i> 2017; <b>147</b>(3): 541–8. <a target=xrefwindow id=d9063e2754 href="http://www.ncbi.nlm.nih.gov/pubmed/28965698">PubMed Abstract </a> | <a target=xrefwindow id=d9063e2757 href="https://doi.org/10.1016/j.ygyno.2017.09.030">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731602853">F1000 Recommendation</a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735476231"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9063e2770 class=n-a></a>Bogani G, Murgia F, Ditto A, <i> et al.</i>: Sentinel node mapping vs. lymphadenectomy in endometrial cancer: A systematic review and meta-analysis. <i>Gynecol Oncol.</i> 2019; <b>153</b>(3): 646–683. <a target=xrefwindow id=d9063e2781 href="http://www.ncbi.nlm.nih.gov/pubmed/30952370">PubMed Abstract </a> | <a target=xrefwindow id=d9063e2784 href="https://doi.org/10.1016/j.ygyno.2019.03.254">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735476231">F1000 Recommendation</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d9063e2797 class=n-a></a>Frumovitz M, Abu-Rustum NR: Tailoring adjuvant treatment in patients with uterine cancer – Authors' reply. <i>Lancet Oncol.</i> 2018; <b>19</b>(12): e656. <a target=xrefwindow id=d9063e2805 href="http://www.ncbi.nlm.nih.gov/pubmed/30507416">PubMed Abstract </a> | <a target=xrefwindow id=d9063e2808 href="https://doi.org/10.1016/S1470-2045(18)30832-5">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727639372"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9063e2817 class=n-a></a>Soliman PT, Westin SN, Dioun S, <i> et al.</i>: A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. <i>Gynecol Oncol.</i> 2017; <b>146</b>(2): 234–9. <a target=xrefwindow id=d9063e2828 href="http://www.ncbi.nlm.nih.gov/pubmed/28528918">PubMed Abstract </a> | <a target=xrefwindow id=d9063e2831 href="https://doi.org/10.1016/j.ygyno.2017.05.016">Publisher Full Text </a> | <a target=xrefwindow id=d9063e2835 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5860676">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727639372">F1000 Recommendation</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d9063e2849 class=n-a></a>Barlin JN, Khoury-Collado F, Kim CH, <i> et al.</i>: The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: Beyond removal of blue nodes. <i>Gynecol Oncol.</i> 2012; <b>125</b>(3): 531–5. <a target=xrefwindow id=d9063e2860 href="http://www.ncbi.nlm.nih.gov/pubmed/22366409">PubMed Abstract </a> | <a target=xrefwindow id=d9063e2863 href="https://doi.org/10.1016/j.ygyno.2012.02.021">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d9063e2872 class=n-a></a>Keys HM, Roberts JA, Brunetto VL, <i> et al.</i>: A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: A Gynecologic Oncology Group study. <i>Gynecol Oncol.</i> 2004; <b>92</b>(3): 744–51. <a target=xrefwindow id=d9063e2883 href="http://www.ncbi.nlm.nih.gov/pubmed/14984936">PubMed Abstract </a> | <a target=xrefwindow id=d9063e2886 href="https://doi.org/10.1016/j.ygyno.2003.11.048">Publisher Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d9063e2895 class=n-a></a>Mariani A, Webb MJ, Keeney GL, <i> et al.</i>: Low-risk corpus cancer: Is lymphadenectomy or radiotherapy necessary? <i>Am J Obstet Gynecol.</i> 2000; <b>182</b>(6): 1506–19. <a target=xrefwindow id=d9063e2906 href="http://www.ncbi.nlm.nih.gov/pubmed/10871473">PubMed Abstract </a> | <a target=xrefwindow id=d9063e2909 href="https://doi.org/10.1067/mob.2000.107335">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d9063e2918 class=n-a></a>Mariani A, Dowdy SC, Cliby WA, <i> et al.</i>: Prospective assessment of lymphatic dissemination in endometrial cancer: A paradigm shift in surgical staging. <i>Gynecol Oncol.</i> 2008; <b>109</b>: 11–8. <a target=xrefwindow id=d9063e2929 href="http://www.ncbi.nlm.nih.gov/pubmed/18304622">PubMed Abstract </a> | <a target=xrefwindow id=d9063e2932 href="https://doi.org/10.1016/j.ygyno.2008.01.023">Publisher Full Text </a> | <a target=xrefwindow id=d9063e2936 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3667391">Free Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d9063e2945 class=n-a></a>Creutzberg CL, van Putten WL, Koper PC, <i> et al.</i>: Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: Multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. <i>Lancet.</i> 2000; <b>355</b>(9213): 1404–11. <a target=xrefwindow id=d9063e2956 href="http://www.ncbi.nlm.nih.gov/pubmed/10791524">PubMed Abstract </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d9063e2964 class=n-a></a>Creutzberg CL, Nout RA, Lybeert MLM, <i> et al.</i>: Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. <i>Int J Radiat Oncol Biol Phys.</i> 2011; <b>81</b>(4): e631–8. <a target=xrefwindow id=d9063e2975 href="http://www.ncbi.nlm.nih.gov/pubmed/21640520">PubMed Abstract </a> | <a target=xrefwindow id=d9063e2978 href="https://doi.org/10.1016/j.ijrobp.2011.04.013">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735572986"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9063e2988 class=n-a></a>Randall ME, Filiaci V, McMeekin DS, <i> et al.</i>: Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer. <i>J Clin Oncol.</i> 2019; JCO1801575. <a target=xrefwindow id=d9063e2996 href="http://www.ncbi.nlm.nih.gov/pubmed/30995174">PubMed Abstract </a> | <a target=xrefwindow id=d9063e2999 href="https://doi.org/10.1200/JCO.18.01575">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735572986">F1000 Recommendation</a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d9063e3012 class=n-a></a>Matei D, Filiaci VL, Randall M, <i> et al.</i>: A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma. <i>J Clin Oncol.</i> 2017; <b>35</b>: 5505. <a target=xrefwindow id=d9063e3023 href="https://doi.org/10.1200/JCO.2017.35.15_suppl.5505">Publisher Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732641164"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9063e3032 class=n-a></a>de Boer SM, Powell ME, Mileshkin L, <i> et al.</i>: Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): Final results of an international, open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncol.</i> 2018; <b>19</b>(3): 295–309. <a target=xrefwindow id=d9063e3043 href="http://www.ncbi.nlm.nih.gov/pubmed/29449189">PubMed Abstract </a> | <a target=xrefwindow id=d9063e3046 href="https://doi.org/10.1016/S1470-2045(18)30079-2">Publisher Full Text </a> | <a target=xrefwindow id=d9063e3050 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5840256">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732641164">F1000 Recommendation</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/2820957"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9063e3063 class=n-a></a>Nout RA, Smit V, Putter H, <i> et al.</i>: Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): An open-label, non-inferiority, randomised trial. <i>Lancet.</i> 2010; <b>375</b>(9717): 816–23. <a target=xrefwindow id=d9063e3074 href="http://www.ncbi.nlm.nih.gov/pubmed/20206777">PubMed Abstract </a> | <a target=xrefwindow id=d9063e3077 href="https://doi.org/10.1016/S0140-6736(09)62163-2">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/2820957">F1000 Recommendation</a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d9063e3090 class=n-a></a>Greven K, Winter K, Underhill K, <i> et al.</i>: Final analysis of RTOG 9708: Adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. <i>Gynecol Oncol.</i> 2006; <b>103</b>(1): 155–9. <a target=xrefwindow id=d9063e3101 href="http://www.ncbi.nlm.nih.gov/pubmed/16545437">PubMed Abstract </a> | <a target=xrefwindow id=d9063e3104 href="https://doi.org/10.1016/j.ygyno.2006.02.007">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d9063e3113 class=n-a></a>Wui-Jin KM, Abu-Rustum NM, Bradley KM: National Comprehensive Cancer Network. Uterine Neoplasms (Version 1.2019). Accessed November 22, 2018<a target=xrefwindow id=d9063e3115 href="http://www.nccn.org/professionals/physician_gls/pdf/uterineneoplasms.pdg">Reference Source</a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d9063e3125 class=n-a></a>Hamilton CA, Cheung MK, Osann K, <i> et al.</i>: Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. <i>Br J Cancer.</i> 2006; <b>94</b>(5): 642–6. <a target=xrefwindow id=d9063e3136 href="http://www.ncbi.nlm.nih.gov/pubmed/16495918">PubMed Abstract </a> | <a target=xrefwindow id=d9063e3139 href="https://doi.org/10.1038/sj.bjc.6603012">Publisher Full Text </a> | <a target=xrefwindow id=d9063e3143 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2361201">Free Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d9063e3152 class=n-a></a>Zhao S, Choi M, Overton JD, <i> et al.</i>: Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. <i>Proc Natl Acad Sci U S A.</i> 2013; <b>110</b>(8): 2916–21. <a target=xrefwindow id=d9063e3163 href="http://www.ncbi.nlm.nih.gov/pubmed/23359684">PubMed Abstract </a> | <a target=xrefwindow id=d9063e3166 href="https://doi.org/10.1073/pnas.1222577110">Publisher Full Text </a> | <a target=xrefwindow id=d9063e3170 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3581983">Free Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d9063e3179 class=n-a></a>Buhtoiarova TN, Brenner CA, Singh M: Endometrial Carcinoma: Role of Current and Emerging Biomarkers in Resolving Persistent Clinical Dilemmas. <i>Am J Clin Pathol.</i> 2016; <b>145</b>(1): 8–21. <a target=xrefwindow id=d9063e3187 href="http://www.ncbi.nlm.nih.gov/pubmed/26712866">PubMed Abstract </a> | <a target=xrefwindow id=d9063e3190 href="https://doi.org/10.1093/ajcp/aqv014">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d9063e3199 class=n-a></a>Boruta DM 2nd, Gehrig PA, Fader AN, <i> et al.</i>: Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. <i>Gynecol Oncol.</i> 2009; <b>115</b>(1): 142–153. <a target=xrefwindow id=d9063e3210 href="http://www.ncbi.nlm.nih.gov/pubmed/19592079">PubMed Abstract </a> | <a target=xrefwindow id=d9063e3213 href="https://doi.org/10.1016/j.ygyno.2009.06.011">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d9063e3222 class=n-a></a>del Carmen MG, Birrer M, Schorge JO: Uterine papillary serous cancer: a review of the literature. <i>Gynecol Oncol.</i> 2012; <b>127</b>(3): 651–61. <a target=xrefwindow id=d9063e3230 href="http://www.ncbi.nlm.nih.gov/pubmed/23000148">PubMed Abstract </a> | <a target=xrefwindow id=d9063e3233 href="https://doi.org/10.1016/j.ygyno.2012.09.012">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d9063e3242 class=n-a></a>Boruta DM 2nd, Gehrig PA, Groben PA, <i> et al.</i>: Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference? <i>Cancer.</i> 2004; <b>101</b>(10): 2214–21. <a target=xrefwindow id=d9063e3253 href="http://www.ncbi.nlm.nih.gov/pubmed/15452833">PubMed Abstract </a> | <a target=xrefwindow id=d9063e3256 href="https://doi.org/10.1002/cncr.20645">Publisher Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d9063e3266 class=n-a></a>Carcangiu ML, Chambers JT: Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: comparison of clinicopathologic features and survival. <i>Int J Gynecol Pathol.</i> 1995; <b>14</b>(1): 30–8. <a target=xrefwindow id=d9063e3274 href="http://www.ncbi.nlm.nih.gov/pubmed/7883423">PubMed Abstract </a> | <a target=xrefwindow id=d9063e3277 href="https://doi.org/10.1097/00004347-199501000-00006">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732916089"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9063e3286 class=n-a></a>Fader AN, Roque DM, Siegel E, <i> et al.</i>: Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. <i>J Clin Oncol.</i> 2018; <b>36</b>(20): 2044–2051. <a target=xrefwindow id=d9063e3297 href="http://www.ncbi.nlm.nih.gov/pubmed/29584549">PubMed Abstract </a> | <a target=xrefwindow id=d9063e3300 href="https://doi.org/10.1200/JCO.2017.76.5966">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732916089">F1000 Recommendation</a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d9063e3313 class=n-a></a>Fiorica JV, Brunetto VL, Hanjani P, <i> et al.</i>: Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. <i>Gynecol Oncol.</i> 2004; <b>92</b>(1): 10–4. <a target=xrefwindow id=d9063e3324 href="http://www.ncbi.nlm.nih.gov/pubmed/14751131">PubMed Abstract </a> | <a target=xrefwindow id=d9063e3327 href="https://doi.org/10.1016/j.ygyno.2003.11.008">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d9063e3336 class=n-a></a>Slayton RE, Blessing JA, Delgado G: Phase II trial of etoposide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. <i>Cancer Treat Rep.</i> 1982; <b>66</b>(8): 1669–71. <a target=xrefwindow id=d9063e3344 href="http://www.ncbi.nlm.nih.gov/pubmed/7105059">PubMed Abstract </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d9063e3353 class=n-a></a>Lincoln S, Blessing JA, Lee RB, <i> et al.</i>: Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. <i>Gynecol Oncol.</i> 2003; <b>88</b>(3): 277–81. <a target=xrefwindow id=d9063e3364 href="http://www.ncbi.nlm.nih.gov/pubmed/12648575">PubMed Abstract </a> | <a target=xrefwindow id=d9063e3367 href="https://doi.org/10.1016/S0090-8258(02)00068-9">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d9063e3376 class=n-a></a>Moore DH, Blessing JA, Dunton C, <i> et al.</i>: Dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: A Phase II study of the Gynecologic Oncology Group. <i>Gynecol Oncol.</i> 1999; <b>75</b>(3): 473–5. <a target=xrefwindow id=d9063e3387 href="http://www.ncbi.nlm.nih.gov/pubmed/10600310">PubMed Abstract </a> | <a target=xrefwindow id=d9063e3390 href="https://doi.org/10.1006/gyno.1999.5652">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d9063e3400 class=n-a></a>Homesley HD, Blessing JA, Sorosky J, <i> et al.</i>: Phase II trial of liposomal doxorubicin at 40 mg/m<sup>2</sup> every 4 weeks in endometrial carcinoma: a Gynecologic Oncology Group Study. <i>Gynecol Oncol.</i> 2005; <b>98</b>(2): 294–8. <a target=xrefwindow id=d9063e3414 href="http://www.ncbi.nlm.nih.gov/pubmed/15975638">PubMed Abstract </a> | <a target=xrefwindow id=d9063e3418 href="https://doi.org/10.1016/j.ygyno.2005.05.016">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d9063e3427 class=n-a></a>Plaxe SC, Blessing JA, Husseinzadeh N, <i> et al.</i>: Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. <i>Gynecol Oncol.</i> 2002; <b>84</b>(2): 241–4. <a target=xrefwindow id=d9063e3438 href="http://www.ncbi.nlm.nih.gov/pubmed/11812081">PubMed Abstract </a> | <a target=xrefwindow id=d9063e3441 href="https://doi.org/10.1006/gyno.2001.6491">Publisher Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d9063e3450 class=n-a></a>Miller DS, Blessing JA, Lentz SS, <i> et al.</i>: A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study. <i>Gynecol Oncol.</i> 2002; <b>87</b>(3): 247–51. <a target=xrefwindow id=d9063e3461 href="http://www.ncbi.nlm.nih.gov/pubmed/12468321">PubMed Abstract </a> | <a target=xrefwindow id=d9063e3464 href="https://doi.org/10.1006/gyno.2002.6804">Publisher Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d9063e3473 class=n-a></a>Fracasso PM, Blessing JA, Molpus KL, <i> et al.</i>: Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. <i>Gynecol Oncol.</i> 2006; <b>103</b>(2): 523–6. <a target=xrefwindow id=d9063e3484 href="http://www.ncbi.nlm.nih.gov/pubmed/16712905">PubMed Abstract </a> | <a target=xrefwindow id=d9063e3487 href="https://doi.org/10.1016/j.ygyno.2006.03.043">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d9063e3496 class=n-a></a>Schilder RJ, Blessing JA, Pearl ML, <i> et al.</i>: Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group. <i>Invest New Drugs.</i> 2004; <b>22</b>(3): 343–9. <a target=xrefwindow id=d9063e3507 href="http://www.ncbi.nlm.nih.gov/pubmed/15122083">PubMed Abstract </a> | <a target=xrefwindow id=d9063e3510 href="https://doi.org/10.1023/B:DRUG.0000026262.77502.31">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d9063e3519 class=n-a></a>Grendys EC Jr, Blessing JA, Burger R, <i> et al.</i>: A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study. <i>Gynecol Oncol.</i> 2005; <b>98</b>(2): 249–53. <a target=xrefwindow id=d9063e3530 href="http://www.ncbi.nlm.nih.gov/pubmed/15978659">PubMed Abstract </a> | <a target=xrefwindow id=d9063e3533 href="https://doi.org/10.1016/j.ygyno.2005.05.017">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/11642958"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9063e3543 class=n-a></a>Aghajanian C, Sill MW, Darcy KM, <i> et al.</i>: Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. <i>J Clin Oncol.</i> 2011; <b>29</b>(16): 2259–65. <a target=xrefwindow id=d9063e3554 href="http://www.ncbi.nlm.nih.gov/pubmed/21537039">PubMed Abstract </a> | <a target=xrefwindow id=d9063e3557 href="https://doi.org/10.1200/JCO.2010.32.6397">Publisher Full Text </a> | <a target=xrefwindow id=d9063e3561 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3107744">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/11642958">F1000 Recommendation</a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725328224"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9063e3574 class=n-a></a>Slomovitz BM, Jiang Y, Yates MS, <i> et al.</i>: Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. <i>J Clin Oncol.</i> 2015; <b>33</b>(8): 930–6. <a target=xrefwindow id=d9063e3585 href="http://www.ncbi.nlm.nih.gov/pubmed/25624430">PubMed Abstract </a> | <a target=xrefwindow id=d9063e3588 href="https://doi.org/10.1200/JCO.2014.58.3401">Publisher Full Text </a> | <a target=xrefwindow id=d9063e3592 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4348638">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725328224">F1000 Recommendation</a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718493928"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9063e3605 class=n-a></a>Baselga J, Campone M, Piccart M, <i> et al.</i>: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. <i>N Engl J Med.</i> 2012; <b>366</b>(6): 520–9. <a target=xrefwindow id=d9063e3616 href="http://www.ncbi.nlm.nih.gov/pubmed/22149876">PubMed Abstract </a> | <a target=xrefwindow id=d9063e3619 href="https://doi.org/10.1056/NEJMoa1109653">Publisher Full Text </a> | <a target=xrefwindow id=d9063e3623 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5705195">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718493928">F1000 Recommendation</a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d9063e3636 class=n-a></a>Slomovitz BM, Filiaci VL, Coleman RL, <i> et al.</i>: GOG 3007, a randomized phase II (RP2) trial of everolimus and letrozole (EL) or hormonal therapy (medroxyprogesterone acetate/tamoxifen, PT) in women with advanced, persistent or recurrent endometrial carcinoma (EC): A GOG Foundation study. <i>Gynecol Oncol.</i> 2018; <b>149</b>(Supplement 1): 2. <a target=xrefwindow id=d9063e3647 href="https://doi.org/10.1016/j.ygyno.2018.04.012">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d9063e3656 class=n-a></a>Howitt BE, Shukla SA, Sholl LM, <i> et al.</i>: Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. <i>JAMA Oncol.</i> 2015; <b>1</b>(9): 1319–23. <a target=xrefwindow id=d9063e3667 href="http://www.ncbi.nlm.nih.gov/pubmed/26181000">PubMed Abstract </a> | <a target=xrefwindow id=d9063e3670 href="https://doi.org/10.1001/jamaoncol.2015.2151">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718017219"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9063e3679 class=n-a></a>Cancer Genome Atlas Research Network, Kandoth C, Schultz N, <i> et al.</i>: Integrated genomic characterization of endometrial carcinoma. <i>Nature.</i> 2013; <b>497</b>(7447): 67–73. <a target=xrefwindow id=d9063e3690 href="http://www.ncbi.nlm.nih.gov/pubmed/23636398">PubMed Abstract </a> | <a target=xrefwindow id=d9063e3693 href="https://doi.org/10.1038/nature12113">Publisher Full Text </a> | <a target=xrefwindow id=d9063e3697 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3704730">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718017219">F1000 Recommendation</a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d9063e3711 class=n-a></a>Talhouk A, McConechy MK, Leung S, <i> et al.</i>: A clinically applicable molecular-based classification for endometrial cancers. <i>Br J Cancer.</i> 2015; <b>113</b>(2): 299–310. <a target=xrefwindow id=d9063e3722 href="http://www.ncbi.nlm.nih.gov/pubmed/26172027">PubMed Abstract </a> | <a target=xrefwindow id=d9063e3725 href="https://doi.org/10.1038/bjc.2015.190">Publisher Full Text </a> | <a target=xrefwindow id=d9063e3729 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4506381">Free Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732115299"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9063e3738 class=n-a></a>Cosgrove CM, Tritchler DL, Cohn DE, <i> et al.</i>: An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer. <i>Gynecol Oncol.</i> 2018; <b>148</b>(1): 174–80. <a target=xrefwindow id=d9063e3749 href="http://www.ncbi.nlm.nih.gov/pubmed/29132872">PubMed Abstract </a> | <a target=xrefwindow id=d9063e3752 href="https://doi.org/10.1016/j.ygyno.2017.10.037">Publisher Full Text </a> | <a target=xrefwindow id=d9063e3756 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5756518">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732115299">F1000 Recommendation</a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727176126"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9063e3769 class=n-a></a>Talhouk A, McConechy MK, Leung S, <i> et al.</i>: Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. <i>Cancer.</i> 2017; <b>123</b>(5): 802–13. <a target=xrefwindow id=d9063e3780 href="http://www.ncbi.nlm.nih.gov/pubmed/28061006">PubMed Abstract </a> | <a target=xrefwindow id=d9063e3783 href="https://doi.org/10.1002/cncr.30496">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727176126">F1000 Recommendation</a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732150125"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9063e3796 class=n-a></a>Halle MK, Tangen IL, Berg HF, <i> et al.</i>: HER2 expression patterns in paired primary and metastatic endometrial cancer lesions. <i>Br J Cancer.</i> 2018; <b>118</b>(3): 378–87. <a target=xrefwindow id=d9063e3807 href="http://www.ncbi.nlm.nih.gov/pubmed/29169184">PubMed Abstract </a> | <a target=xrefwindow id=d9063e3810 href="https://doi.org/10.1038/bjc.2017.422">Publisher Full Text </a> | <a target=xrefwindow id=d9063e3814 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5808034">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732150125">F1000 Recommendation</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d9063e3827 class=n-a></a>De Grève J, Teugels E, Geers C, <i> et al.</i>: Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. <i>Lung Cancer.</i> 2012; <b>76</b>(1): 123–7. <a target=xrefwindow id=d9063e3838 href="http://www.ncbi.nlm.nih.gov/pubmed/22325357">PubMed Abstract </a> | <a target=xrefwindow id=d9063e3841 href="https://doi.org/10.1016/j.lungcan.2012.01.008">Publisher Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1059703"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9063e3850 class=n-a></a>Geyer CE, Forster J, Lindquist D, <i> et al.</i>: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. <i>N Engl J Med.</i> 2006; <b>355</b>(26): 2733–43. <a target=xrefwindow id=d9063e3861 href="http://www.ncbi.nlm.nih.gov/pubmed/17192538">PubMed Abstract </a> | <a target=xrefwindow id=d9063e3864 href="https://doi.org/10.1056/NEJMoa064320">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1059703">F1000 Recommendation</a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d9063e3878 class=n-a></a>Chambers JT, MacLusky N, Eisenfield A, <i> et al.</i>: Estrogen and progestin receptor levels as prognosticators for survival in endometrial cancer. <i>Gynecol Oncol.</i> 1988; <b>31</b>(1): 65–77. <a target=xrefwindow id=d9063e3889 href="http://www.ncbi.nlm.nih.gov/pubmed/3410357">PubMed Abstract </a> | <a target=xrefwindow id=d9063e3892 href="https://doi.org/10.1016/0090-8258(88)90270-3">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d9063e3901 class=n-a></a>Thigpen JT, Brady MF, Alvarez RD, <i> et al.</i>: Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. <i>J Clin Oncol.</i> 1999; <b>17</b>(6): 1736–44. <a target=xrefwindow id=d9063e3912 href="http://www.ncbi.nlm.nih.gov/pubmed/10561210">PubMed Abstract </a> | <a target=xrefwindow id=d9063e3915 href="https://doi.org/10.1200/JCO.1999.17.6.1736">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d9063e3924 class=n-a></a>Stelloo E, Nout RA, Osse EM, <i> et al.</i>: Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts. <i>Clin Cancer Res.</i> 2016; <b>22</b>(16): 4215–24. <a target=xrefwindow id=d9063e3935 href="http://www.ncbi.nlm.nih.gov/pubmed/27006490">PubMed Abstract </a> | <a target=xrefwindow id=d9063e3938 href="https://doi.org/10.1158/1078-0432.CCR-15-2878">Publisher Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d9063e3947 class=n-a></a>Said R, Hong DS, Warneke CL, <i> et al.</i>: P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. <i>Oncotarget.</i> 2013; <b>4</b>(5): 705–14. <a target=xrefwindow id=d9063e3958 href="http://www.ncbi.nlm.nih.gov/pubmed/23670029">PubMed Abstract </a> | <a target=xrefwindow id=d9063e3961 href="https://doi.org/10.18632/oncotarget.974">Publisher Full Text </a> | <a target=xrefwindow id=d9063e3965 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3742831">Free Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d9063e3974 class=n-a></a>Wheler JJ, Janku F, Naing A, <i> et al.</i>: <i>TP53</i> Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. <i>Mol Cancer Ther.</i> 2016; <b>15</b>(10): 2475–85. <a target=xrefwindow id=d9063e3988 href="http://www.ncbi.nlm.nih.gov/pubmed/27466356">PubMed Abstract </a> | <a target=xrefwindow id=d9063e3992 href="https://doi.org/10.1158/1535-7163.MCT-16-0196">Publisher Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d9063e4001 class=n-a></a>Schwaederlé M, Lazar V, Validire P, <i> et al.</i>: VEGF-A Expression Correlates with <i>TP53</i> Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy. <i>Cancer Res.</i> 2015; <b>75</b>(7): 1187–90. <a target=xrefwindow id=d9063e4015 href="http://www.ncbi.nlm.nih.gov/pubmed/25672981">PubMed Abstract </a> | <a target=xrefwindow id=d9063e4019 href="https://doi.org/10.1158/0008-5472.CAN-14-2305">Publisher Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d9063e4029 class=n-a></a>Mallen AR, Filiaci VL, Levine DA, <i> et al.</i>: Evidence for synthetic lethality between bevacizumab and chemotherapy in advanced, p53 null endometrial cancers. <i>Oral presentation at: 2018 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer; March 24-27</i>, New Orleans, LA. 2018. <a target=xrefwindow id=d9063e4037 href="https://sgo.confex.com/sgo/2018/meetingapp.cgi/Paper/9382">Reference Source</a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/730367783"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9063e4046 class=n-a></a>Mjos S, Werner HMJ, Birkeland E, <i> et al.</i>: <i>PIK3CA</i> exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer. <i>Sci Rep.</i> 2017; <b>7</b>(1): 10240. <a target=xrefwindow id=d9063e4060 href="http://www.ncbi.nlm.nih.gov/pubmed/28860563">PubMed Abstract </a> | <a target=xrefwindow id=d9063e4064 href="https://doi.org/10.1038/s41598-017-10717-z">Publisher Full Text </a> | <a target=xrefwindow id=d9063e4067 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5578954">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/730367783">F1000 Recommendation</a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d9063e4081 class=n-a></a>Janku F, Wheler JJ, Westin SN, <i> et al.</i>: PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring <i>PIK3CA</i> mutations. <i>J Clin Oncol.</i> 2012; <b>30</b>(8): 777–82. <a target=xrefwindow id=d9063e4095 href="http://www.ncbi.nlm.nih.gov/pubmed/22271473">PubMed Abstract </a> | <a target=xrefwindow id=d9063e4099 href="https://doi.org/10.1200/JCO.2011.36.1196">Publisher Full Text </a> | <a target=xrefwindow id=d9063e4102 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3295566">Free Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d9063e4111 class=n-a></a>Janku F, Hong DS, Fu S, <i> et al.</i>: Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. <i>Cell Rep.</i> 2014; <b>6</b>(2): 377–87. <a target=xrefwindow id=d9063e4122 href="http://www.ncbi.nlm.nih.gov/pubmed/24440717">PubMed Abstract </a> | <a target=xrefwindow id=d9063e4125 href="https://doi.org/10.1016/j.celrep.2013.12.035">Publisher Full Text </a> | <a target=xrefwindow id=d9063e4129 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4409143">Free Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d9063e4138 class=n-a></a>Oza AM, Elit L, Tsao MS, <i> et al.</i>: Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. <i>J Clin Oncol.</i> 2011; <b>29</b>(24): 3278–85. <a target=xrefwindow id=d9063e4149 href="http://www.ncbi.nlm.nih.gov/pubmed/21788564">PubMed Abstract </a> | <a target=xrefwindow id=d9063e4152 href="https://doi.org/10.1200/JCO.2010.34.1578">Publisher Full Text </a> | <a target=xrefwindow id=d9063e4156 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3158598">Free Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d9063e4165 class=n-a></a>Athanassiadou P, Athanassiades P, Grapsa D, <i> et al.</i>: The prognostic value of PTEN, p53, and beta-catenin in endometrial carcinoma: a prospective immunocytochemical study. <i>Int J Gynecol Cancer.</i> 2007; <b>17</b>(3): 697–704. <a target=xrefwindow id=d9063e4176 href="http://www.ncbi.nlm.nih.gov/pubmed/17504383">PubMed Abstract </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d9063e4185 class=n-a></a>Terakawa N, Kanamori Y, Yoshida S: Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. <i>Endocr Relat Cancer.</i> 2003; <b>10</b>(2): 203–8. <a target=xrefwindow id=d9063e4193 href="http://www.ncbi.nlm.nih.gov/pubmed/12790783">PubMed Abstract </a> | <a target=xrefwindow id=d9063e4196 href="https://doi.org/10.1677/erc.0.0100203">Publisher Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d9063e4205 class=n-a></a>Salvesen HB, MacDonald N, Ryan A, <i> et al.</i>: PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. <i>Int J Cancer.</i> 2001; <b>91</b>(1): 22–6. <a target=xrefwindow id=d9063e4216 href="http://www.ncbi.nlm.nih.gov/pubmed/11149415">PubMed Abstract </a> | <a target="xrefwindow" id="d9063e4219" href="https://doi.org/10.1002/1097-0215(20010101)91:1<22::AID-IJC1002&gt;3.0.CO;2-S">Publisher Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d9063e4228 class=n-a></a>Slomovitz BM, Lu KH, Johnston T, <i> et al.</i>: A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. <i>Cancer.</i> 2010; <b>116</b>(23): 5415–9. <a target=xrefwindow id=d9063e4239 href="http://www.ncbi.nlm.nih.gov/pubmed/20681032">PubMed Abstract </a> | <a target=xrefwindow id=d9063e4242 href="https://doi.org/10.1002/cncr.25515">Publisher Full Text </a> | <a target=xrefwindow id=d9063e4246 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5120730">Free Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d9063e4255 class=n-a></a>Bachmann IM, Halvorsen OJ, Collett K, <i> et al.</i>: EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. <i>J Clin Oncol.</i> 2006; <b>24</b>(2): 268–73. <a target=xrefwindow id=d9063e4266 href="http://www.ncbi.nlm.nih.gov/pubmed/16330673">PubMed Abstract </a> | <a target=xrefwindow id=d9063e4269 href="https://doi.org/10.1200/JCO.2005.01.5180">Publisher Full Text </a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d9063e4278 class=n-a></a>Mizuuchi H, Nasim S, Kudo R, <i> et al.</i>: Clinical implications of K-ras mutations in malignant epithelial tumors of the endometrium. <i>Cancer Res.</i> 1992; <b>52</b>(10): 2777–81. <a target=xrefwindow id=d9063e4289 href="http://www.ncbi.nlm.nih.gov/pubmed/1581890">PubMed Abstract </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d9063e4298 class=n-a></a>Falchook GS, Lewis KD, Infante JR, <i> et al.</i>: Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. <i>Lancet Oncol.</i> 2012; <b>13</b>(8): 782–9. <a target=xrefwindow id=d9063e4309 href="http://www.ncbi.nlm.nih.gov/pubmed/22805292">PubMed Abstract </a> | <a target=xrefwindow id=d9063e4312 href="https://doi.org/10.1016/S1470-2045(12)70269-3">Publisher Full Text </a> | <a target=xrefwindow id=d9063e4316 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4109286">Free Full Text </a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d9063e4326 class=n-a></a>Cox AD, Fesik SW, Kimmelman AC, <i> et al.</i>: Drugging the undruggable RAS: Mission possible? <i>Nat Rev Drug Discov.</i> 2014; <b>13</b>(11): 828–51. <a target=xrefwindow id=d9063e4337 href="http://www.ncbi.nlm.nih.gov/pubmed/25323927">PubMed Abstract </a> | <a target=xrefwindow id=d9063e4340 href="https://doi.org/10.1038/nrd4389">Publisher Full Text </a> | <a target=xrefwindow id=d9063e4344 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4355017">Free Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d9063e4353 class=n-a></a>Zighelboim I, Goodfellow PJ, Gao F, <i> et al.</i>: Microsatellite instability and epigenetic inactivation of <i>MLH1</i> and outcome of patients with endometrial carcinomas of the endometrioid type. <i>J Clin Oncol.</i> 2007; <b>25</b>(15): 2042–8. <a target=xrefwindow id=d9063e4367 href="http://www.ncbi.nlm.nih.gov/pubmed/17513808">PubMed Abstract </a> | <a target=xrefwindow id=d9063e4371 href="https://doi.org/10.1200/JCO.2006.08.2107">Publisher Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d9063e4380 class=n-a></a>Piulats JM, Matias-Guiu X: Immunotherapy in Endometrial Cancer: In the Nick of Time. <i>Clin Cancer Res.</i> 2016; <b>22</b>(23): 5623–5. <a target=xrefwindow id=d9063e4388 href="http://www.ncbi.nlm.nih.gov/pubmed/27697995">PubMed Abstract </a> | <a target=xrefwindow id=d9063e4391 href="https://doi.org/10.1158/1078-0432.CCR-16-1820">Publisher Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d9063e4400 class=n-a></a>Hampel H, Frankel W, Panescu J, <i> et al.</i>: Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. <i>Cancer Res.</i> 2006; <b>66</b>(15): 7810–7. <a target=xrefwindow id=d9063e4411 href="http://www.ncbi.nlm.nih.gov/pubmed/16885385">PubMed Abstract </a> | <a target=xrefwindow id=d9063e4414 href="https://doi.org/10.1158/0008-5472.CAN-06-1114">Publisher Full Text </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d9063e4423 class=n-a></a>Mo Z, Liu J, Zhang Q, <i> et al.</i>: Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer. <i>Oncol Lett.</i> 2016; <b>12</b>(2): 944–50. <a target=xrefwindow id=d9063e4434 href="http://www.ncbi.nlm.nih.gov/pubmed/27446374">PubMed Abstract </a> | <a target=xrefwindow id=d9063e4437 href="https://doi.org/10.3892/ol.2016.4744">Publisher Full Text </a> | <a target=xrefwindow id=d9063e4441 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4950473">Free Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d9063e4450 class=n-a></a>Vanderstraeten A, Luyten C, Verbist G, <i> et al.</i>: Mapping the immunosuppressive environment in uterine tumors: Implications for immunotherapy. <i>Cancer Immunol Immunother.</i> 2014; <b>63</b>(6): 545–57. <a target=xrefwindow id=d9063e4461 href="http://www.ncbi.nlm.nih.gov/pubmed/24658839">PubMed Abstract </a> | <a target=xrefwindow id=d9063e4464 href="https://doi.org/10.1007/s00262-014-1537-8">Publisher Full Text </a> | <a target=xrefwindow id=d9063e4468 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4024136">Free Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727600468"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9063e4478 class=n-a></a>Ott PA, Bang YJ, Berton-Rigaud D, <i> et al.</i>: Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. <i>J Clin Oncol.</i> 2017; <b>35</b>(22): 2535–41. <a target=xrefwindow id=d9063e4489 href="http://www.ncbi.nlm.nih.gov/pubmed/28489510">PubMed Abstract </a> | <a target=xrefwindow id=d9063e4492 href="https://doi.org/10.1200/JCO.2017.72.5952">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727600468">F1000 Recommendation</a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d9063e4505 class=n-a></a>Engelsen IB, Akslen LA, Salvesen HB: Biologic markers in endometrial cancer treatment. <i>APMIS.</i> 2009; <b>117</b>(10): 693–707. <a target=xrefwindow id=d9063e4513 href="http://www.ncbi.nlm.nih.gov/pubmed/19775337">PubMed Abstract </a> | <a target=xrefwindow id=d9063e4516 href="https://doi.org/10.1111/j.1600-0463.2009.02467.x">Publisher Full Text </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727742822"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9063e4525 class=n-a></a>Kato S, Krishnamurthy N, Banks KC, <i> et al.</i>: Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary. <i>Cancer Res.</i> 2017; <b>77</b>(16): 4238–46. <a target=xrefwindow id=d9063e4536 href="http://www.ncbi.nlm.nih.gov/pubmed/28642281">PubMed Abstract </a> | <a target=xrefwindow id=d9063e4539 href="https://doi.org/10.1158/0008-5472.CAN-17-0628">Publisher Full Text </a> | <a target=xrefwindow id=d9063e4543 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5729906">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727742822">F1000 Recommendation</a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d9063e4556 class=n-a></a>Coleman RL, Sill MW, Thaker PH, <i> et al.</i>: A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecol Oncol.</i> 2015; <b>138</b>(1): 30–5. <a target=xrefwindow id=d9063e4567 href="http://www.ncbi.nlm.nih.gov/pubmed/25887099">PubMed Abstract </a> | <a target=xrefwindow id=d9063e4570 href="https://doi.org/10.1016/j.ygyno.2015.04.005">Publisher Full Text </a> | <a target=xrefwindow id=d9063e4574 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4469526">Free Full Text </a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727195783"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9063e4583 class=n-a></a>Longoria TC, Eskander RN: Immunotherapy in endometrial cancer - an evolving therapeutic paradigm. <i>Gynecol Oncol Res Pract.</i> 2015; <b>2</b>: 11. <a target=xrefwindow id=d9063e4591 href="http://www.ncbi.nlm.nih.gov/pubmed/27231571">PubMed Abstract </a> | <a target=xrefwindow id=d9063e4594 href="https://doi.org/10.1186/s40661-015-0020-3">Publisher Full Text </a> | <a target=xrefwindow id=d9063e4597 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4881063">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727195783">F1000 Recommendation</a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d9063e4610 class=n-a></a>Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. <i>Nat Rev Cancer.</i> 2012; <b>12</b>(4): 252–64. <a target=xrefwindow id=d9063e4618 href="http://www.ncbi.nlm.nih.gov/pubmed/22437870">PubMed Abstract </a> | <a target=xrefwindow id=d9063e4621 href="https://doi.org/10.1038/nrc3239">Publisher Full Text </a> | <a target=xrefwindow id=d9063e4624 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4856023">Free Full Text </a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d9063e4634 class=n-a></a>Iwai Y, Ishida M, Tanaka Y, <i> et al.</i>: Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. <i>Proc Natl Acad Sci U S A.</i> 2002; <b>99</b>(19): 12293–7. <a target=xrefwindow id=d9063e4645 href="http://www.ncbi.nlm.nih.gov/pubmed/12218188">PubMed Abstract </a> | <a target=xrefwindow id=d9063e4648 href="https://doi.org/10.1073/pnas.192461099">Publisher Full Text </a> | <a target=xrefwindow id=d9063e4652 href="http://www.ncbi.nlm.nih.gov/pmc/articles/129438">Free Full Text </a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735415442"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9063e4661 class=n-a></a>Makker V, Rasco D, Vogelzang NJ, <i> et al.</i>: Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. <i>Lancet Oncol.</i> 2019; <b>20</b>(5): 711–8. <a target=xrefwindow id=d9063e4672 href="http://www.ncbi.nlm.nih.gov/pubmed/30922731">PubMed Abstract </a> | <a target=xrefwindow id=d9063e4675 href="https://doi.org/10.1016/S1470-2045(19)30020-8">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735415442">F1000 Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 12 Jun 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-849/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-849/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Rebecca and John Moores UC San Diego Cancer Center, 3855 Health Sciences Drive #0987, La Jolla, CA, 92093-0987, USA<br/> <p> <div class=margin-bottom> Lindsey M. Charo <br/> <span>Roles: </span> Conceptualization, Investigation, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Steven C. Plaxe <br/> <span>Roles: </span> Conceptualization, Supervision, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/8-849/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 12 Jun 2019, 8:849 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.17408.1">https://doi.org/10.12688/f1000research.17408.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2019 Charo LM and Plaxe SC. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=19036 data-id=17408 data-downloads="" data-views="" data-scholar="10.12688/f1000research.17408.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/8-849/v1/pdf?article_uuid=c33363e7-865d-4bbd-8969-eb53571975cc" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.17408.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Charo LM and Plaxe SC. Recent advances in endometrial cancer: a review of key clinical trials from 2015 to 2019 [version 1; peer review: 2 approved] <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):849 (<a href="https://doi.org/10.12688/f1000research.17408.1" target=_blank>https://doi.org/10.12688/f1000research.17408.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=17408 id=mobile-track-article-signin-17408 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/17408?target=/articles/8-849/v1"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=19036 /> <input name=articleId type=hidden value=17408 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Jan Persson</strong>, Department of Obstetrics and Gynecology, Skane University Hospital, Lund University, Sweden </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Anil K Sood</strong>, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> Anil K Sood is a consultant for Merck and Kiyatec, receives research funding from M-Trap, and is a stock holder in Biopath. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 12 Jun 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-849/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-849/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=51794-49228></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=51793-49229></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/8-849/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>12 Jun 19</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Jan Persson</strong>, Department of Obstetrics and Gynecology, Skane University Hospital, Lund University, Sweden </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Anil K Sood</strong>, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> Anil K Sood is a consultant for Merck and Kiyatec, receives research funding from M-Trap, and is a stock holder in Biopath. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/8-849/v1&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/8-849/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances in endometrial cancer: a...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/8-849/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/8-849/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/8-849/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Charo LM and Plaxe SC');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/8-849/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/8-849",
            templates : {
                twitter : "Recent advances in endometrial cancer: a review of key clinical.... Charo LM and Plaxe SC, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/8-849/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances in endometrial cancer: a review of key clinical trials from 2015 to 2019", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances in endometrial cancer: a review of key clinical trials from 2015 to 2019", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/17408/19036")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "19036");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "49228": 0,
                           "49229": 1,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "cbdbc38e-a034-4083-a993-6a593c96392e";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-849.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-849.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-849.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/8-849.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/8-849.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>